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Abstract
Glycogen Synthase Kinase 3 beta (GSK-3β) is an important node of regulation in many
cellular signaling pathways including insulin and Wnt. Previous work has shown that
ubiquitous deletion of GSK-3β is lethal and causes various skeletal abnormalities, but it is
not known whether these defects are skeleton-intrinsic. A second GSK-3 protein which
shares almost complete homology, GSK-3α, has been shown to have completely overlapping
roles with the β form in some cases and independent functions in other cases. Therefore
examination of the role of GSK-3β in skeletal development is very poignant.
To examine the role of GSK-3β in skeletal development we used three models: 1. Ex vivo
tibia organ cultures treated with pharmacological inhibitors, 2. In vivo cartilage-specific
GSK-3β deletion, 3. In vivo bone-specific GSK-3β deletion.

The tibia organ culture

experiment revealed that inhibiting both GSK-3 forms caused increased bone growth. We
also demonstrated that GSK-3 effects on chondrocyte proliferation were PI3K-dependent and
regulated by GSK-3α whereas effects on hypertrophy were PI3K-independent and GSK-3β
regulated.

However when GSK-3β was deleted specifically in cartilage, there was no

change in growth or growth plate morphology. One unique finding was that GSK-3α was
upregulated in the pre-hypertrophic/hypertrophic region of mutant mice, presumably through
a compensating mechanism.
Since the global knockout (KO) showed a skeletal phenotype and our cartilage-specific KO
did not, we postulated that GSK-3β function in osteoblast was important for skeletal
development. To test this we generated osteoblast-specific GSK-3β KO mice. These mice
displayed skeletal phenotypes seen in the global deletion study plus several more since we
were able to study postnatal development. These mice also displayed a metabolic phenotype.
The mice had lower blood glucose and insulin but their pancreases were unchanged. Most
interestingly, almost 100% of the mutant males died with high blood glucose and damage to
their urogenital track, all reminiscent of type II diabetes development.

iii

In conclusion we showed that cartilage GSK-3β is not important for skeletal development but
both GSK-3s are required to regulate growth.

We showed that osteoblast GSK-3β is

important for skeletal development and whole body metabolic regulation.

Keywords
Glycogen synthase kinase 3 alpha, GSK-3β, diabetes, insulin, glucose, growth plate,
osteoblast, chondrocytes, skeletal development
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Chapter 1

1

Introduction

1.1 Skeletogenesis
Once thought to be just scaffolding for muscle attachment, the skeleton has been recently
shown to have many other functions. One of these emerging roles is bone functioning as
an endocrine organ to regulate energy metabolism, which will be discussed in great detail
later.

In retrospect, this role appears logical since the adult human skeleton makes up

14% of total body weight and therefore the development, growth and regulation of such a
large portion of the body would require a large amount of energy.
The bones of our skeleton form through two different processes, endochondral and
intramembranous ossification.

The development and growth of the skeletal elements

involves several cell types, e.g. osteoblasts (bone forming cells), osteoclasts (bone
resorbing cells), and chondrocytes (cartilage forming cells). Coordination between cells
types is very complex and involves both intrinsic and extrinsic factors.

1.1.1

Intramembranous Ossification

The mandible, clavicle, some of the facial bones and the flat bones of the cranium
develop through intramembranous ossification (1).

This process is triggered by

epithelial-mesenchymal interactions, which cause the mesenchymal cells to differentiate
into preosteoblasts.

These cells condense, proliferate and differentiate into mature

osteoblasts (1-3). The osteoblasts start to produce and deposit bone matrix, thus forming
ossification centers. Intramembranous ossification does not need a cartilage template to
form bone unlike endochondral ossification.
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1.1.2

Endochondral Ossification

Endochondral ossification is the process by which most of the bones of the body are
formed. This includes bones of the appendicular (long bones) and axial (vertebrae, ribs)
skeleton (1,4,5). This process involves the production of a cartilage template that is
replaced by bone.
Just like intramembranous ossification, endochondral bone formation is also initiated by
the condensation of mesenchymal cells, which in this process differentiate into
chondrocytes (4,6) (Figure 1.1). Chondrocytes are the cell type that produces cartilage
matrix. This cartilage matrix is rich in type II collagen and the proteoglycan aggrecan
(6).

Surrounding these cartilage condensations is a layer of cells called the

perichondrium (6)(Figure 1.1). The chondrocytes in the middle of the condensations exit
the cell cycle and enlarge, becoming hypertrophic chondrocytes. These hypertrophic
chondrocytes change their gene expression profile and start producing type X collagen.
These cells also direct the cells in the surrounding perichondrium to differentiate into
osteoblast and produce the bone of the bone collar (6) (Figure 1.2).

Hypertrophic

chondrocytes ultimately undergo apoptosis, leaving behind cartilage matrix scaffolding
that is invaded by blood vessels (which are attracted by VEGF produced by hypertrophic
chondrocytes).

The blood vessels bring in pre-osteoblasts and osteoclasts that

differentiate and convert the cartilage matrix to true bone, forming the primary
ossification center (primary spongiosa) (6) (Figure 1.2). The ends of the bones are next
invaded by blood vessel and ossified by osteoblasts, forming secondary ossification
centres.

3

Figure 1.1 (1) Early endochondral bone formation

4

Figure 1.2 (2) Late Endochondral Bone Formation
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The newly formed bone has a dense bone collar surrounding the outer surface of the
middle (diaphysis) of the bone with spongy (trabecular) bone on the inside or marrow
cavity. This primary ossification centre is capped at either end by a layer of cartilage
called the growth plate, which, as the name suggests, is responsible for longitudinal
growth. At the ends of the bone (epiphysis) is the secondary ossification centre, which is
covered by another group of chondrocytes and cartilage called articular cartilage.
Articular cartilage is primarily responsible for aiding articulation of joints by reducing
friction and acting as a shock absorber (Figure 1.3).

1.1.3

Cartilage Growth Plate

The growth plate is essential in determining a person’s height. Situated at the either end
of long bones they drive bone growth from the primary ossification centre in both
directions. The growth plate has three distinct zones that can be identified by
morphology, cell cycle progression, and gene expression patterns (Figure 1.4). The zone
furthest from the centre of the bone is the resting zone where these chondrocytes serve as
a reserve bank of chondrocytes for the rest of the growth plate (7). These cells can be
identified morphologically as they appear small and round (Figure 1.4). In terms of cell
cycle, these cells are not proliferating very rapidly. As the resting cells move closer to
the diaphysis they start to proliferate very rapidly and produce cartilage matrix. Both
these attributes force the chondrocytes to adopt their characteristic morphology, columns
of flattened cells. These chondrocytes arrange in columns and form the proliferating
zone (7) (Figure 1.4). The last zone of the growth plate, discussed previously, is the
hypertrophic zone. This zone borders the primary ossification zone. This zone can be
identified by the very large chondrocytes and changes in both cartilage
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Figure 1.3 (3) Mature bone
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Figure 1.4 (4) Growth plate zones
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matrix produced and gene expression profiles (4,6,7) (Figure 1.4).

There is also a

transitional stage between the proliferating and hypertrophic called pre-hypertrophic that
is unique and important. The chondrocytes of the pre-hypertrophic zone express genes
important for cell cycle exit and a combination of genes expressed by proliferating and
hypertrophic cells (8,9).
The rate at which the chondrocytes progress through these maturation stages determines
the longitudinal bone growth. The enlargement of the hypertrophic cells, which increase
5-10 times in volume compared to proliferating chondrocytes, is responsible for a large
portion of bone elongation (10,11). In fact, the chondrocyte height is responsible for up
to 60% of longitudinal bone growth, while the remainder of growth is due to matrix
synthesis and chondrocyte proliferation (10,12-15).

1.2 Growth Plate Regulation
Controlled and regulated growth is extremely important for an organism as too much or
too little could be detrimental to survival. There are many regulatory molecules, from
transcription factors, to secreted and to systemic factors, that affect various aspects of the
growth plate chondrocyte’s life cycle and ultimately growth.

1.2.1

Systemic Factors

A variety of systemic factors affect bone growth some of which are growth hormone
(GH) and insulin-like growth factor-1 (IGF-1), thyroid hormones (T3 and T4), and
glucocorticoids (GC).
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Growth hormone has long been known to effect growth, hence its name. Children with
high GH levels exhibit gigantism whereas insufficient GH causes impaired growth as in
children with mutation in the GH receptor (16). Most of the effects of GH on the
skeleton are carried out by liver-derived IGF-1. In mice, a reduction in the amount of
circulating IGF-1 results in a reduction of longitudinal growth (17), where administration
of exogenous IGF-1 restores growth in mice and humans with GH receptor mutations
(18,19). GH also has local action on the growth plate, stimulating growth, through to
local production of IGF-1 (16). The main effect of GH on the growth plate chondrocytes
is to stimulate proliferation (13) (Figure 1.5).
Thyroid hormones are systemic factors that affect skeletal growth. In humans with
hypothyroidism, longitudinal bone growth is slowed, growth plates are thinned and
chondrocyte hypertrophy is impaired (20). In contrast, hyperthyroidism causes increased
growth velocity in children but also leads to premature growth plate fusion and short
stature (21,22). Thyroid hormone has been shown to have several effects on chondrocytes
including inducing maturation (23), and induction of hypertrophy without inducing
proliferation (24-26). Mice heterozygous for an inactivating mutation in the thyroid
hormone receptor (α) displayed longitudinal growth retardation and impaired
chondrocyte hypertrophy (27).

So it appears that the GH/IGF axis effects the

proliferation of growth plate chondrocytes whereas the thyroid hormone affects
hypertrophy (Figure 1.5).
Another example of a systemic factor is represented by glucocorticoids (GCs). Various
childhood diseases require GC treatment which causes decreased bone volume and
growth retardation (28). On the contrary, GC deficiency is associated with tall statue
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(29).

GC is a potent inhibitor of chondrogenesis as treatment with dexamethasone

inhibits chondrocyte proliferation and matrix production (30).

1.2.2

Local Factors

As well as being controlled by systemic signals, the three zones of the growth plate also
regulate themselves through locally secreted factors. Some of the local secreted factors
that control bone growth are Indian hedgehog (Ihh), parathyroid hormone-related peptide
(PTHrP), bone morphogenic proteins (BMP), Wnt family proteins, and fibroblast growth
factors (FGF).
Indian hedgehog (Ihh) is a secreted factor that is produced by prehypertrophic
chondrocytes.

Ihh stimulates chondrocyte proliferation and inhibits chondrocyte

hypertrophy (31-34).

The inhibition of hypertrophy is dependent on Ihh-stimulated

upregulation of parathyroid hormone-related peptide (Figure 1.5). Another function of
Ihh is to cause mesenchymal cells in the perichondrium to differentiate into osteoblasts
and form the bone collar (33,35).
Parathyoid hormone-related peptide (PTHrP) is expressed in perichondral and early
proliferating chondrocytes and diffuses away from the site of production to regulate cells
expressing PTH/PTHrP receptor (36). The receptor is expressed in low amounts in
proliferating chondrocytes and expressed in much greater amounts by cells that are
initiating an inhibition of proliferation.

The role of PTHrP is to maintain the

chondrocytes proliferating and prevents hypertrophy (37) (Figure 1.5). As chondrocytes
proliferate and move farther from the site of PTHrP production, they lose PTHrP
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signaling, stop proliferating, undergo the early steps of hypertrophy, and start producing
Ihh. The Ihh produced then feeds back to maintain the production of PTHrP.
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-β
superfamily and play many roles in skeletogenesis. Proliferating chondrocytes express
BMP7 whereas the pre-hypertrophic and hypertrophic chondrocytes express BMP6 (38).
BMP signaling promotes chondrocyte proliferation in the growth plate (39,40) (Figure
1.5). The role that BMPs play in regulating the hypertrophic chondrocytes is much less
clear, although it appears important for normal rates of onset and progression of
hypertrophy (4). BMP signaling induces Ihh expression and the reverse is also true,
although effects on the growth plate are independent of each other (39,41).
The Wnt family of secreted proteins and their signaling pathway play an important role in
growth plate regulation. Several Wnt members are expressed in the growth plate with the
highest expression in the proliferating and hypertrophic zones (42). This signaling within
the growth plate is important for chondrocyte survival, proliferation and hypertrophy (4345) (Figure 1.5).

When the target of the canonical Wnt pathway, β-catenin, is

constitutively active, it suppresses hypertrophy in immature chondrocytes but promotes
terminal differentiation in mature chondrocytes (46). In the early proliferating zone, the
canonical Wnt signaling effect on survival appears to be downstream of Ihh, however in
late proliferating it appears to be independent of Ihh (44).

Furthermore, the Wnt

antagonist, secreted frizzled receptor 1, is expressed in prehypertrophic chondrocytes and
likely acts as a regulator of Wnt’s effects on chondrocyte maturation (47).
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The last of the local factors that will be discussed here are fibroblast growth factors
(FGFs). The proliferating and early hypertrophic chondrocytes express fibroblast growth
factor receptor-3 (FGFR3), where its activation leads to an inhibition of chondrocyte
proliferation and acceleration of hypertrophy (48). Activating mutations in the human
FGFR3 gene lead to short-limbed dwarfisms including the most common form of
dwarfism, achondroplasia (49). Treatment of limb explant cultures with FGF2 leads to a
reduction in the number of cells expressing Ihh (48). Forced expression of Ihh inhibits
FGF2’s acceleration of hypertrophy, which suggests that FGF acts upstream of Ihh.
However, the effects of FGF2 on proliferation are not counteracted by the forced
expression of Ihh, which indicates that FGF suppression of proliferation is independent of
Ihh. In fact, the effects of FGF signaling on chondrocyte proliferation, Ihh expression
and hypertrophy are antagonized by BMP signaling (48)(Figure 1.5).

1.2.3

Transcription Factors

The transcription factor Sox9 is thought of as the major chondrocyte transcription factor.
Sox9 is essential for converting cells of condensation into chondrocytes and acts at every
stage of chondrocyte differentiation (6). Sox9 is expressed by proliferating but not
hypertrophic chondrocytes and induces components of the cartilage matrix, including
collagen type II and aggrecan (50). Study of Sox9 in vivo has been difficult as deletion in
undifferentiated limb bud mesenchymal cells results in complete failure of
chondrogenesis. When Sox9 is deleted in chondrocytes expressing collagen type II, the
cells fail to undergo further differentiation to reach the stages of the growth plate (51).
These studies and others show that Sox9 is required for normal rates of chondrocyte
proliferation and delaying the onset of hypertrophy (4) (Figure 1.5). There is evidence
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Figure 1.5 (5) Regulation of the growth plate
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that Sox9 is the target downstream of PTH/PTHrP receptor to mediate the inhibition of
hypertrophy in response to PTHrP (4).

There is also a human condition called

campomelic dysplasia that is caused by defects in Sox9. This condition is characterized
by craniofacial defects, kyphoscoliosis, bowing and angulation of long bones among
other features (52,53).
Originally the transcription factor Runx2 was thought of as the major osteoblast specific
transcription factor as mice with deleted Runx2 have no osteoblasts (54,55). However, it
is now clear that Runx2 is also important in growth plate chondrocyte regulation as it
drives proliferative chondrocytes to differentiate further into hypertrophic chondrocytes
(50) (Figure 1.4). Runx2 is the transcriptional activator of hypertrophic chondrocyte
markers such as collagen type X and also activates the Ihh promoter (56). Runx2
expression is inhibited by PTHrP signaling, which is thought to contribute to the ability
of PTHrP to inhibit hypertrophy (57). Furthermore, the activity of Runx2 is repressed by
Sox9 through a direct interaction between the two transcription factors (58).

1.2.4

Glycogen Synthase Kinase 3 Beta

One key regulatory molecule that has been implicated in many if not all of the factors
described above is glycogen synthase kinase 3 beta (GSK-3β).

GSK-3β has been

implicated in regulation of the Wnt/β-catenin pathway (59-62), the insulin/IGF pathway
(63-66), thyroid hormone signaling (67), glucocorticoid signaling (68), Runx2 activity
and stability (69,70), BMP signaling (71,72), Sox9 activity and expression (43,73), PTH
signaling (74), Ihh signaling (44,75), and FGF signaling (76). GSK-3β is an important
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node of regulation for many pathways important to skeletal development and therefore
requires a closer examination.

1.3 GSK-3β
Glycogen Synthase Kinase 3 was first discovered in 1978 by Sir Philip Cohen from the
University of Dundee, Scotland (77). Students of Sir Cohen then partially purified and
characterized GSK and identified 3 serine residues on glycogen synthase (GS) that are
targeted by GSK-3 (78,79). The final purification to homogeneity was performed by two
more of his students, Brian Hemmings and James Woodgett (80,81).

Dr. James

Woodgett is now a leader in GSK-3 research and contributed to the following studies by
providing the floxed GSK-3β mice.
GSK-3 is a highly conserved protein kinase for which genes have been identified in every
eukaryotic genome studied to date (82). In mammals, GSK-3 is encoded by two genes,
Gsk3α and Gsk3β. Gsk3α encodes a protein 51 kDa in size whereas the GSK-3β protein
is 47 kDa (83) (Figure 1.6). The two GSK-3 proteins share almost complete sequence
identity between their protein kinase domains and a high degree of conservation around
their ATP binding sites (83). The greatest structural difference between the two is an
amino-terminal, glycine rich region specific to GSK-3α that accounts for the 4 kDa size
difference between the proteins. Both mammalian GSK-3 proteins are inhibited by
amino-terminal serine phosphorylation, GSK-3α on S21 and GSK-3β on S9 (Figure 1.6).
There are at least two ways in which GSK-3β activity is inhibited physiologically,
through direct phosphorylation (Ser9) by a variety of kinases (65) or through disruption
of a protein complex involved in canonical Wnt signaling (84). Several protein kinases
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Figure 1.6 (6) Structure of the two glycogen synthase kinase 3 proteins
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are capable of inactivating GSK-3. The most highly studied is PKB/Akt (85,86), which
inhibits GSK-3 in response to insulin (or IGFs) (65) (Figure 1.7).

The secreted

glycoproteins of the Wnt family initiate a canonical signaling cascade following binding
to 2 membrane-bound receptors (FZD and Lrp5 or 6). Canonical Wnt signaling disrupts
the protein complex of adenomatous polyposis coli (APC), Axin, casein kinase 1 (CK1)
and glycogen synthase kinase 3 (GSK-3) that in the absence of Wnt ligands
phosphorylates β-catenin (Figure 1.8).

Phosphorylation of β-catenin results in

ubiquitination and degradation of β-catenin.

Upon Wnt signaling, this process is

inhibited (disruption of destruction complex), β-catenin accumulates and translocates to
the nucleus where it binds to the transcription factors lymphoid enhancer-binding factor 1
(LEF) / T cell-specific transcription factor (TCF) and ultimately affects gene transcription
(87)(Figure 1.8). GSK-3 is thus the common focal point of several integrated signaling
systems and a wide selection of cellular stimulants.
GSK-3 is a serine/threonine kinase capable of phosphorylating a large number of
substrates including glycogen synthase, from where its name originated, and β-catenin. It
has been proposed that there may be two pools of GSK-3β; one involved in canonical
Wnt signaling and another involved in other pathways and directly phosphorylated
(59,88). It has also been proposed that GSK-3α and GSK-3β are functionally redundant
and may be able to compensate for lack of the other (62), whereas others have shown
differential roles for the two isoforms (89). These differences are likely due to tissue- or
stimulus-specific effects. Tissue specificity of GSK-3 is a widely debated topic in the
GSK-3 field recently and is a logical explanation for the numerous functions
(differentiation, polarity, migration, apoptosis, development, metabolism, translation, and
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Figure 1.7 (7) The Insulin signaling pathway
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Figure 1.8 (8) The canonical Wnt signaling pathway
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transcription) and various pathways regulated by GSK-3. While GSK-3 is a key regulator
in many tissues throughout the body, including brain, heart, and bone, it is likely that it
does not have the same cellular functions or is regulated by the same upstream pathways
in all cells/tissues. Tissue specificity will depend on cellular receptors, state, regulatory
molecules, transcription factors, and cellular machinery present.
As a result of the versatility of GSK-3, it has been studied extensively in many
pathological conditions such as cancer (90,91), brain disorders such as schizophrenia and
bipolarism (92,93) and diabetes (94,95).

GSK-3β is aggressively being targeted as

possible drug target to treat the aforementioned disorders (96).

1.3.1

Role of GSK-3β in bone development

One of the most studied bone regulatory pathways is canonical Wnt signaling through βcatenin, which is required for normal chondrocyte and osteoblast differentiation
(43,97,98). Another pathway that has been identified as crucial for bone development is
insulin/insulin like growth factor (IGF) (99-101). These pathways and others important in
skeletal development are directly regulated by GSK-3.
One of the earliest and best-characterized GSK-3 inhibitors, which is still widely used, is
lithium (Li) (102,103). The mode of inhibition by lithium is competition for Mg2+
binding sites, which are required for GSK-3β activation (104). Treatment of wild-type
mice with lithium significantly increased bone mass in vivo (105). In addition, several
ATP competitive inhibitors have been developed, such as SB-216763 and SB-415286
(106,107).

These and other inhibitors have been used in various in vitro and in vivo

experiments to determine the molecular and physiological roles of GSK-3.

New
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inhibitors are being developed and tested on a continuing basis. An orally bioavailable
GSK-3α/β dual inhibitor was used to show an increase in osteoblast differentiation in
vitro and increase bone mass and strength in vivo in rats (108).

The use of inhibitors

identified GSK-3 as an important molecule for bone development and possibly as a target
for osteoporosis treatment.
Many transgenic mouse models involving various components of the canonical Wnt
pathway display skeletal phenotypes. Mice overexpressing Wnt4a in chondrocytes are
dwarfed with craniofacial abnormalities and delayed ossification of lumbar vertebrae
(109). Two mouse loss-of-function models for the Lrp5 gene displayed decreased bone
mass (110,111), whereas gain-of-function mice conversely had high bone mass
(112,113).

β-catenin was examined in many mouse models.

The total β-catenin

knockout is embryonically lethal at E7.5 (114), and therefore other strategies were
adopted to study β-catenin function in vivo.

β-catenin deletion in mesenchymal

precursors resulted in enhanced chondrogenesis (115,116). However, β-catenin deletion
later in development under control of the Col2a1 promoter caused decreased chondrocyte
proliferation and maturation (43). These models indicate a differential role for β-catenin
at different stages of chondrocyte maturation. A group produced a mouse model that
overexpressed ICAT, a β-catenin inhibitor, under the Col2a1 promoter (117). These
mice were born with normal size, but became increasingly runted and showed decreased
chondrocyte proliferation and increased hypertrophic chondrocyte apoptosis.
Finally, several groups have examined whether genetic manipulation of GSK-3β causes
skeletal defects (118,119).

The GSK-3β total KO was originally described to be

embryonically lethal (118). In a later study, mutant animals survived to P0 with cleft
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palates, bifid sternum and delayed ossification of the sternum, skull, ear bones, and
cranial base (119). Heterozygous deletion of GSK-3β also caused a skeletal phenotype,
namely increased ossification, clavicle abnormalities and increased bone reabsorption
(69). The total and heterozygous KO of GSK-3β seemed to display opposite phenotypes,
where heterozygous mutants showed increased ossification and null animals displayed
delayed ossification. Importantly, these findings were obtained with conventional KO
mice where Gsk3b was inactivated in all cells of the body; the role of this gene in
individual skeletal cells are therefore not understood.
All these findings point towards an important role of GSK-3β in skeletal development;
however the specific role in the various pathways controlling skeletal development is still
unclear. The developed mouse models to study GSK-3β in skeletal development have
shown an equally complicated pattern of phenotypes that seem contradictory to each
other, increased bone formation versus delayed bone development and ossification.

1.4 Bone as an endocrine organ
Recently a new function has been emerging for bone, as an endocrine organ. For many
years it has been known that certain hormones affect bone. However, hormone systems
generally operate with a negative feedback loop, suggesting that bone would need to
respond with a hormone of its own. To date, the only such hormone is osteocalcin (120).
The search for the elusive bone hormone started by narrowing the search to proteins that
are specific to osteoblasts and are secreted into circulation. This simplified matters
greatly as osteocalcin is one of only a handful of proteins that is osteoblast-specific and
furthermore is secreted into the circulation (121,122). The first osteocalcin knockout
mice were produced in 1996 and shown to have high bone mass but no mention of any
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metabolic changes was made at this time (123). It was not until 2007 that osteocalcin
would be identified as a bone hormone affecting metabolism (120).

Osteocalcin

undergoes posttranslational modification where glutamic acid residues are carboxylated
(Gla) (121). This carboxylation gives osteocalcin a high affinity for mineral ions and
anchors it in bone mineral matrix. However, both gain- and loss-of-function studies have
failed to determine a role for osteocalcin in extracellular matrix in vivo (123,124).
The publication that first identified osteocalcin as a bone hormone also identified a
regulator of the metabolic effects, Esp (120). Esp encodes a protein that is expressed in
osteoblasts and Sertoli cells called receptor-like protein tyrosine phosphatase (OST-PTP)
(125). The Esp-/- mice where born with a 3-fold reduction in blood glucose when
measured prior to first feeding, and 35% of the KO pups died before weaning (120).
Even though the Esp gene is only expressed in osteoblast and Sertoli cells, the Esp KO
mice displayed changes in their pancreas and fat. The mice had increased pancreatic
insulin, islet size, and beta cell mass as well increased serum insulin levels and insulin
sensitivity (120). The KO mice also showed decreased gonadal fat pads and increased
adiponectin levels (an adipokine enhancing insulin sensitivity) (120).
Osteocalcin (OCN)-/- mice were also examined for metabolic changes and were shown to
have a completely opposite phenotype to the Esp KO. The OCN KO mice had increased
blood glucose and fat mass (120). They also displayed decreased serum insulin, insulin
sensitivity and adiponectin (120). To test whether OCN was the active hormone, a
variety of co-culture assays were performed using osteoblast, β-cells, and adipocytes.
The experiments showed that OCN was able to increase insulin secretion from the β-cells
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as well as adiponectin from adipocytes. However, OCN expression was not altered in the
Esp KO mice, suggesting that Esp must be affecting OCN activity. From this the
researchers discovered that the active bone hormone was the uncarboxylated form of
osteocalcin, which was regulated by ESP (120).

This ability of uncarboxylated

osteocalcin to regulate pancreas insulin secretion/blood glucose regulation and adipocyte
adiponectin production was confirmed in wild-type mice (126).
The new role for osteocalcin as the bone hormone did not actually show a possible link to
GSK-3β until 2010 when two papers were published by two different groups (127,128).
Although the connection to GSK-3β was not explicitly established in these publications,
they both characterized mice that had the insulin receptor deleted specifically in
osteoblasts. Given the well-documented regulation of the insulin pathway by GSK-3β,
the connection between the two can be made (63-66,129). Osteoblast-specific insulin
receptor (Ob-IR) KO mice have increased blood glucose and decreased serum insulin
(127).

Insulin tolerance was decreased and likewise insulin resistance increased

(127,128). It was also shown that the Ob-IR KO mice had increased fat and decreased
bone acquisition (128). Both papers discovered different mechanisms through which the
insulin receptor regulated the undercarboxylated osteocalcin. One paper showed that the
insulin receptor inhibits FoxO1, which regulates bone resorption by osteoclasts (127).
This resorption, and more specifically the acidity of the resorption fluid, decarboxylated
the osteocalcin in the bone matrix and released it to circulation (127).

This is an

interesting finding as it ties the energy extensive process of bone remodeling to energy
metabolism. The other group found that the insulin receptor inhibited the transcription
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factor Twist2, which in turn inhibited Runx2. The level of Runx2 controlled the amount
of undercarboxylated osteocalcin released (128).

1.5 Overall objectives and hypothesis
1.5.1

Rationale

By understanding the signaling pathways involved in bone development and maintenance
one can start to understand and manipulate pathways involved in the development of
disease states. It has been shown numerous times that GSK-3β regulates numerous
pathways and molecules involved in skeletal development and growth by regulating
various cellular activities such as proliferation, survival, cell cycle progression, and
angiogenesis. It is interesting that typically GSK-3 negatively regulates pathways and
acts like a “brake” on the anabolic processes. Therefore, removal or release of the brake
through inhibition or genetic manipulation should accelerate proliferation, survival, cell
cycle progression, and angiogenesis.

GSK-3 inhibitors have demonstrated the

importance of GSK-3β in bone mass regulation and identified this molecule as a
therapeutic target for osteoporosis. Furthermore, genetic deletion of GSK-3β causes
mortality and skeletal malformations. Finally, the heterozygous GSK-3β mice display a
high bone mass phenotype. Highlighted here is the direct evidence of GSK-3β; however,
there is a plethora of indirect evidence from studies manipulating pathways components
either upstream or downstream of GSK-3β. These studies usually focus on components
of the insulin/IGF or Wnt/β-catenin pathways of which I mostly focus on as well.
However, two recent reviews compiled lists of extracellular factors shown to regulate
GSK-3 activity as well as a list of the known GSK-3 substrates of which there is greater
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than 100 (130,131). This multitude of pathways and substrates as well as the complexity
of signaling regulation highlights the biological importance of GSK-3β.
No one to date has been able to study the role of GSK-3β in postnatal bone development
as the total GSK-3β KOs are lethal and no one knows if the skeletal effects are skeletal
cell autonomous. I therefore set out to produce cartilage- and bone-specific GSK-3β
deletions to study the role of GSK-3β in skeletal development.

1.5.2

Overall Hypothesis

Deletion of GSK-3β in specific skeletal tissue, cartilage and bone, will cause an
increase in cell proliferation and survival altering bone growth and development.

1.5.3

Aims

Aim 1: To determine the role that GSK-3β plays in growth plate function,
endochondral bone formation and bone growth.
Aim 2: To determine the role of GSK-3β signaling in osteoblasts during postnatal
bone development.
Aim 3: To investigate the whole body metabolic effects of deleting GSK-3β in
osteoblasts.
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Chapter 2

2

Deletion of glycogen synthase kinase-3beta in
cartilage results in upregulation of glycogen
synthase kinase-3alpha protein expression

This chapter has been reproduced from: Gillespie JR, Ulici V, Dupuis H, Higgs A,
DiMattia A, Patel S, Woodgett JR, Beier F. Deletion of Glycogen synthase kinase-3beta
in cartilage results in upregulation of Glycogen synthase kinase-3alpha protein
expression. Endocrinology. 2011 May;152(5):1755-66. Epub 2011 Feb 15.
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2.1 Introduction
Most bones develop through endochondral ossification, in which a cartilage scaffold is
first produced by chondrocytes and then converted to calcified bone tissue by boneforming cells, osteoblasts.

Chondrocytes of the growth plate are responsible for

longitudinal growth of endochondral bones (1,2). The growth plate is divided into three
distinct zones that can be identified by either histological features, rate of cell cycle
progression or marker gene expression. The “resting” zone is farthest from the mid bone
(diaphysis) and consists of small chondrocytes with little cytoplasm and relatively low
rates of proliferation. Some of these cells mature into “proliferative” zone chondrocytes
that undergo rapid proliferation, resulting in flattened columnar cells surrounded by
cartilage matrix. The proliferating chondrocytes then withdraw from the cell cycle and
differentiate further into prehypertrophic and ultimately “hypertrophic” chondrocytes
residing at the interface between growth plate cartilage and ossified bone. These
hypertrophic cells represent the terminal differentiation stage and secrete a large amount
of matrix and regulatory proteins. Finally, the hypertrophic cells die by apoptosis and
leave behind a cartilage matrix that is invaded by blood vessels accompanied by
osteoblast (bone-forming) and osteoclast (bone-resorbing) precursors, ultimately resulting
in the replacement of cartilage by bone tissue (3-8).
The rate in which the chondrocytes progress through the zones of the growth plate
determine the longitudinal growth of bone. This rate is consequently extremely important
for normal skeletal development and final height in humans and is therefore tightly
regulated both intrinsically and extrinsically by a complicated network of signaling
pathways(2,9-11).
Many of these signaling pathways have been linked to the regulatory kinase glycogen
synthase kinase three, GSK-3. Two pathways with relevance to this study are insulin or
insulin-like growth factor (IGF)/PI3K/AKT/GSK-3 (12-16) and Wnt/GSK-3/β-catenin
(14,17,18). GSK-3 is a serine/threonine kinase capable of phosphorylating a large number
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of substrates including glycogen synthase, from where its name originated, but its role in
physiology has expanded exponentially since its discovery. GSK-3 is an unusual kinase
in that it is constitutively active and usually negatively regulates pathways (19-21).
Mammals have two GSK-3 proteins, GSK-3α and GSK-3β (encoded by different, highly
homologous genes), with masses of 51kDa and 47kDa, respectively. Regulation of GSKα and β can occur through at least two mechanisms: a) through direct phosphorylation
(Ser21

and

Ser9

of

GSK-3α

and

β,

respectively),

for

example

by

the

phosphatidylinositide 3-kinase (PI3K)/AKT (12) signaling pathway, or b) through
disruption of the protein complex involved in canonical Wnt signaling (22). Potential
crosstalk between these two pathways is highly debated as is the relationship between the
two GSK-3 proteins, GSK-3α and β.

Many studies have demonstrated that

phosphorylation of GSK-3 does not affect β-catenin levels whereas other studies have
suggested it can (23-27). Likewise there is evidence for both overlapping and distinct
roles of GSK-3α and GSK-3β (16,17,28-31). Tissue-specific roles and relations could
explain some of these seemingly contradictory results (16,32).
Several groups have examined how genetic manipulation of Gsk3b affects the skeleton
(33,34).

The germline homozygous deletion of Gsk3b shows a variable phenotype

depending on the genetic background and can result in embryonic lethality (33) or
survival to P0 with cleft palate, bifid sternum and delayed ossification of the sternum,
skull, ear bones, and cranial base (34). Heterozygous deletion of Gsk3b also causes a
skeletal phenotype with increased ossification, clavicle abnormalities and increased bone
resorption (35). It would appear that these opposing skeletal phenotypes are Gsk3b
dosage-dependent effects; however, all these are phenotypes based on germline loss of
Gsk3β. Consequently it is unclear whether these skeletal phenotypes are cell or tissue
autonomous. Interestingly, GSK-3α global KO mice have also been created; these are
viable and fertile with similar body mass compared to controls (36) but display
abnormalities in glucose metabolism and brain structure (16,36,37) without any described
skeletal abnormalities. The two global KO models suggest that GSK-3β may play a more
important role in skeletal development than GSK-3α. Here we address the role of GSK-3
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signaling in chondrocytes using an organ culture system and cartilage-specific
inactivation of the Gsk3b gene.

2.2 Material and Methods
2.2.1

Materials

The following antibodies were utilized in this study: actin A5441 (Sigma); Cyclin D1
RM-9104-S1 (Neomarkers); goat anti-rabbit hrp sc-2004, goat anti-mouse hrp sc-2005,
p57/Kipp2 sc-8298 (Santa Cruz); GSK-3β #9315, pGSK-3β #9336, GSK-3α #9338,
pGSK-3α & β #9331, β-catenin #9562 (Cell Signaling). General chemicals and supplies
were purchased from Sigma and VWR, organ culture reagents were from Invitrogen.

2.2.2

Mouse breeding and genotyping

Mice homozygous for floxed Gsk3b alleles (Gsk3bfl/fl) have been described previously
(16, 38). Gsk3bfl/fl mice were crossed with mice expressing cre recombinase under
control of the cartilage-specific mouse Col2a1 promoter, donated by Drs. R. St-Arnaud
and G. Karsenty, that we previously utilized in our lab (39, 40). Mice heterozygous for
the floxed Gsk3b allele and expressing Col2a1 cre were backcrossed with homozygous
Gsk3b floxed mice. The offspring from these crosses were analyzed. Mice were exposed
to a 12 hr light-dark cycle and fed tap water and regular chow ad libitum. All procedures
involving animals were approved by the University of Western Ontario Animal Care and
Use Committee. PCR genotyping was performed from ear notch DNA using primers 5’GGGGCAACCTTAATTTCATT-3’

(forward)

and

5’-

TCTGGGCTATAGCTATCTAGTAACG-3’ (reverse) for GSK-3β for 30 cycles of 96 οC
55sec, 56.5οC 45 sec, 68 οC 2:45min to amplify. The cre transgene was detected using the
primers

5’-CACACTGTGTAGTGCTTCGT-3’

(forward)
ο

and

5’ο

CCTCCAAACCATCCAAGAT-3’ (reverse) using 40 cycles of 95 C 45sec, 58 C 30sec,
72 οC 1min.
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2.2.3

Organ culture

Tibiae were isolated from embryonic day 15.5, e15.5, mice and cultured for 6 days in
serum-free medium containing alpha MEM, ascorbic acid, β-glycerophosphate, bovine
serum albumin, glutamine, and penicillin-streptomycin as described, without exogenous
growth factors (15, 41). Following dissection, tibiae were incubated in medium
overnight, then treated with DMSO (control) or the GSK-3 inhibitor SB415286 (SB86;
10 µM), PI3K inhibitor LY 294002 (10 µM LY), or a combination of the two inhibitors.
Please note that SB86 inhibits both GSK-3 proteins (42). Media and inhibitor were
changed every 48 hrs. Length of tibiae was measured before start of treatment and at the
end of 6 days. Each independent experiment consisted of 5-6 tibiae per treatment; data
represent averages from at least 3 independent experiments. These bones were then either
stained with Alcian Blue/Alizarin Red or prepared for paraffin embedding, sectioned and
analyzed by immunohistochemistry (IHC).

2.2.4

Tibia staining

Tibia staining was performed as described previously (39, 43). Organ culture tibia
isolated from e15.5 embryos were dehydrated in 95% ethanol for 24 hours, followed by
acetone for 24 hours. Tibias were stained with 0.015% Alcian blue, 0.05% alizarin red
and 5% acetic acid in 70% ethanol. The stained tibias were stored in glycerol/ethanol
(1:1).

Images were taken with a Nikon SMZ1500 dissecting microscope with a

Photometrics Coolsnap camera using ImageMaster 5.0 software. At least 3 independent
experiments containing 4-6 tibias per treatment (n) were used.

2.2.5

Histology and immunohistochemistry (IHC)

Organ culture and isolated P0 tibias were fixed in 4% paraformaldehyde overnight and
decalcified with 0.1M EDTA/PBS at room temperature before paraffin embedding and
sectioning at the Robarts Research Institute Molecular Pathology Core Facility (London,
ON). Five µm sections were dewaxed in xylene followed by a graded series of ethanol
washes (100% x 2, 95% x 1, 70% x 1). Sections were stained with either H&E or
Safranin O/Fast green (39, 40, 43, 44). For IHC, sections were incubated in 3% H2O2 for
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15 min at room temperature, followed by antigen retrieval by incubation in either 10 mM
sodium citrate at 95 οC for 30 min or 0.1% triton X for 10 min, followed by blocking with
5% goat serum in PBS. Sections were incubated with primary antibody overnight at 4 οC,
washed (PBS x 4), and secondary antibody was applied according to manufacturers’
recommendations. For detection, DAB substrate was used and counterstained with
Methyl Blue. All images were taken with a Leica DME microscope with a Qimaging
Mircropublishes 5.0 RTV camera using QCapture Pro 5.1 software.
Quantification of IHC was conducted depending on the target protein. For quantification
of PCNA IHC, the positively stained (brown) and total nuclei were counted to determine
the fraction of PCNA positive cells in the growth plate. The quantification of p57 protein
in the growth plate was conducted by measuring the length (proximal to distal) of the
prehypertrophic zone where darkly stained (brown) nuclei are present.

2.2.6

Western blot analyses

Fresh calvaria, cartilage from the epiphyseal ends of long bones (humerus, femur, tibia),
and organs were dissected from P0 mice in cold Puck’s solution A (PSA) (39, 45).
Samples were flash frozen in RIPA buffer and stored at -20 οC overnight, then
homogenized, sonicated and centrifuged. Total protein content was determined; 25-35µg
total protein (depending on protein yield) was loaded per lane in precast NuPAGE Novex
Midi Tris-Acetate Gels and separated using the XCell Surelock Mini-cell (Invitrogen)
system. Gels were blotted using XCell II Blot Module (Invitrogen) as per manufacturer’s
instructions. Blots were blocked in 5% BSA TBST solution for 1 hour, and then probed
with primary antibody overnight at 4 οC. After washing (TBST), membranes were
incubated with appropriate secondary antibody (hrp-conjugated) for one hour at room
temperature, and the resultant signal was detected using the ECL detection system
(Amersham). Representative blots from at least 3 independent pairs of littermates are
shown. Quantitative densitometry analysis was conducted using a ChemiImager 5500
system, subtracting background and normalizing to β-actin loading control signal.
Densitometry results were converted relative to control, allowing comparison between
blots and compared statistically by t-test analysis.
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2.2.7

Statistical analysis

All data were collected from at least 3 independent organ culture trial or pairs of
littermates. Data was expressed as mean ±SE, and p values under 0.05 were considered
significant. For general measurements and comparisons between two groups of data,
statistical significance was determined by unpaired t-test comparing control to treated
(SB86) or control to cartilage specific deletion of GSK-3β (KO) littermates using
GraphPad Prism 3.00 for Windows. Western blot densitometry data were normalized to
controls and compared by t-test. Comparison of multiple treatments was done using oneway Anova (normal distribution analyzed) and a Tukey post-test.

2.3 Results
2.3.1

GSK-3 expression in the growth plate

To determine the expression patterns of both GSK-3 proteins in the growth plate in vivo,
we performed immunohistochemistry (IHC) on wild type P0 mouse tibia. GSK-3β was
expressed at low levels in chondrocytes at the articular surface and hardly detectable by
IHC in resting and proliferating chondrocytes, but strongly expressed in prehypertrophic
and hypertrophic chondrocytes (Fig. 2.1). GSK-3β in the hypertrophic chondrocytes
appears both cytoplasmic and nuclear with the highest concentration being nuclear. In
contrast, GSK-3α showed strong expression throughout the growth plate and appeared to
be more cytoplasmic than β. Both proteins were also expressed in the perichondrium
where GSK-3β appeared confined to the layer of cells closest to hypertrophic
chondrocytes and GSK-3α was again more uniformly expressed through the cells of the
perichondrium.

2.3.2

GSK-3 inhibition increases bone growth and affects growth
plate morphology

To determine the role that GSK-3 plays in endochondral bone growth, e15.5 tibia organ
culture were cultured for 6 days with the pharmacological GSK-3 inhibitor SB415286
(SB86; 10 µM) that inhibits both GSK-3 proteins (42). Longitudinal growth over this
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Figure 2.1 (9)- Expression of GSK-3 proteins in the growth plate
Expression of GSK-3α and β proteins in the growth plate of wildtype P0 tibia was
analyzed by IHC. While GSK-3β expression was detected in chondrocytes of the
articular surface (Arrow) and in particular in prehypertrophic and hypertrophic
chondrocytes, GSK-3α is expressed in all zones of the growth plate. Both proteins are
also expressed in the perichondrium (P), although GSK-3β was restricted to the cells
closest to hypertrophic chondrocytes (H) and GSK-3α was again uniformly expressed
throughout the cells of the perichondrium.
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time was compared to controls treated with DMSO. Tibia treated with SB86 grew 31%
more than controls over the 6 days of organ culture (Fig 2.2 A, B). A similar trend,
though not statistically significant with a completed n of 3, was also observed using
another GSK-3 inhibitor, 10µM SB216763. SB86 was used exclusively for the remainder
of the experiments. Interestingly, this increase in bone growth did not affect the overall
length of the growth plate of the treated tibia (Fig 2.2 C, D). However, inhibition of GSK3 did affect the organization and relative lengths of the zones within the growth plate (Fig
2.2 E, F). The division between the resting and proliferating zones was much less distinct
in the SB86-treated bones and therefore the zone measurements combined both resting
and proliferating zones for accuracy of measurements. The resting and proliferating
zones of the treated tibia were 13% longer than the controls (Fig 2.2 E), whereas the
length of hypertrophic zone was significantly decreased by 57% (Fig 2.2 F). Since the
inhibition of GSK-3 caused increased tibia growth but the total growth plate length was
not increased, we examined the mineralized portion of the tibia (Fig 2.2 G).

The

mineralized portion of the tibia was found to be significantly longer as a ratio of total
tibia length. These results together suggest that inhibition of GSK-3 promotes long bone
longitudinal growth by increasing bone formation.

2.3.3

GSK-3 inhibition rescues most effects of PI3K inhibition in
organ culture

GSK-3 activity is regulated through N-terminal phosphorylation by the insulin/PI3K/Akt
pathway (12, 46) as well the IGF/PI3K/Akt pathway that is an important regulator of
chondrocyte physiology (15, 47). We previously showed that PI3K inhibition decreased
bone growth and the length of the proliferating and hypertrophic zones (15). Given that
PI3K activates PKB/Akt that in turn phosphorylates and inhibits GSK-3, inhibition of
PI3K should activate GSK-3 and therefore have opposite effects as inhibiting GSK-3.
Furthermore, if inactivation of GSK-3 is one of the main effectors of PI3K signaling in
endochondral bone growth, then GSK-3 inhibition should rescue the effects of PI3K
inhibition, at least in part. To explore interactions between PI3K/Akt and GSK-3, the
effects of treatments with a PI3K inhibitor (10 µM LY 294002, LY) in combination with
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Figure 2.2 (10) - Inhibition of GSK-3 increases bone growth and changes growth
plate organization
E15.5 mouse tibiae were cultured in organ culture (OC) for 6 days with a
pharmacological inhibitor of GSK-3 (10µM SB415286; SB86) or DMSO (Cont). (A)
Representative picture of tibiae stained with Alizarin Red (Bone) and Alcian Blue
(Cartilage). (B) Quantification of growth (mm) of the tibia during the 6 days of treatment.
(C) H&E-stained paraffin sections of organ culture tibiae comparing morphology and
growth plate zones, e.g. resting and proliferating zones (R/P) and hypertrophic zone (H).
(D) Length (mm) of the proximal tibia growth plate in control and SB86-treated tibiae.
(E) Resting and proliferating zone length (mm) in control and GSK-3 inhibited organ
culture.

(F) Hypertrophic zone length (mm) in control and GSK-3 inhibited organ

culture. (G) Quantification of the proportion of mineralized bone relative to the whole
tibia length in control and GSK-3-inhibited organ culture. All data were compared using
t-test analysis, significant differences are denoted by asterisk (n > 8, *: p < 0.05).
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the GSK-3 inhibitor (10 µM SB415286, SB86) on tibia organ cultures were examined
(Fig 2.3).
To confirm that the inhibition of PI3K would indeed affect the phosphorylation of GSK-3
in our tibia organ culture model, IHC analyses was conducted using antibodies specific to
phosphorylated GSK-3β (Fig 2.3A upper) or to phosphorylated forms of both GSK-3
proteins (Fig 2.3 A lower). These data shows that phosphorylation for GSK-3β was
consistently decreased with LY treatment through the pre-hypertrophic/hypertrophic
zones where GSK-3β is primarily expressed in the growth plate (Fig 2.3 A upper). The
IHC detecting both phospho-GSK-3α and β demonstrated a decrease in the GSK-3
phosphorylation through the resting and proliferating zones but a less significant change
in the pre-hypertrophic zone (Fig 2.3 A lower). This suggests that GSK-3α, which is
more widely expressed in the growth plate, is the predominate GSK-3 form targeted by
inhibition of the PI3K pathway through the resting and proliferating zones, whereas
GSK-3β is the main target the prehypertrophic zone.
Consistent with our earlier studies, SB86 (Fig 2.2) increased and LY (15) decreased tibia
growth in culture (Fig 2.3 B, C). The effect of the PI3K inhibitor was partially recovered
by the combination with the GSK-3 inhibitor (LY + SB86) (Fig 2.3 B, C). None of the
treatments had significant effects on the total length of the growth plates. Similar to the
bone growth, the combination of the inhibitors was able to partially recover the effect of
PI3K inhibition on the length of the resting/proliferative zone (Fig 2.3 D), while both
inhibitors individually and in combination reduced the length of the hypertrophic zone
(Fig 2.3 E).

2.3.4

Chondrocyte-specific ablation of GSK-3β in vivo

To determine if the ex vivo tibia organ cultures results would translate into an in vivo
model and to address the roles of individual GSK-3 proteins, we generated mice with
cartilage-specific loss of GSK-3β. Mice homozygote for the floxed alleles of GSK-3β
(Gsk3bfl/fl) (16, 38) were crossed with mice heterozygote for the floxed allele and
expressing cre recombinase gene under control of the mouse collagen II (Col2a1)
promoter (Gsk3bfl/wt cre+) (39, 48). This breeding scheme produced cartilage-specific
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Figure 2.3 (11) Interaction of PI3K and GSK-3 signaling in organ culture
Tibia organ cultures (e15.5) were treated with GSK-3 inhibitor (10µM SB415286
(SB86)), PI3K inhibitor (10 µM LY 294002 (LY)), a combination of both inhibitors
(10µM SB415286 + 10 µM LY 294002 (SB86 + LY)), or DMSO (Cont) for six days. (A)
IHC analyses of GSK-3 phosphorylation using phospho-specific antibodies specific for
GSK-3β (upper panel) or both GSK-3α and β (lower panel). (B) Representative picture
of tibiae after six days of culture stained with Alizarin Red (Bone) and Alcian Blue
(Cartilage). (C) Quantification of longitudinal growth of tibiae (mm) over 6 days of
culture. (D) Resting and proliferating zone length (µm) of bones treated with the various
inhibitors. (E) Hypertrophic zone length (µm) of bones treated with the various
inhibitors. All data were compared using one-way ANOVA with a Tukey post-test
analysis, significant differences are denoted by asterisk (n = 3, *: p < 0.05).
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GSK-3β deletion in (Gsk3bfl/fl cre+) referred to as knockout mice (KO), heterozygous
mice (Gsk3bfl/wt cre+), as well as control (Cont) littermates (Gsk3bfl/fl cre- or Gsk3bfl/wt
cre). Efficiency of GSK-3β deletion was determined through Western blot analysis and
immunohistochemistry (Fig 2.4).

Long bone growth plate extracts from P0 mice

demonstrated an 80% reduction in GSK-3β protein in KO cartilage (Fig 2.4 A, B).
Immunohistochemistry (IHC) of P0 tibia paraffin section demonstrated strong expression
of GSK-3β in the prehypertrophic and hypertrophic zones of control mice with virtually a
complete loss of signal in KO littermates (Fig 2.4 C). GSK-3β protein levels were
explored in many tissues to evaluate the specificity of the deletion (Fig 2.4 D, E).
Calvaria tissue samples showed that GSK-3β expression was not affected in bone tissue
(Fig 2.4 D). No loss of GSK-3β protein was observed in any other tissues of KO mice
(Fig 2.4 E).
The cartilage specific GSK-3β KO mice did not display an observable skeletal
phenotype. The size and weight of KO mice were similar to those of control sex-matched
littermates throughout their life, from birth to 1 year (data not shown). The length of the
tibiae at birth P0 (Fig 2.4 F) and at P21 were not significantly different from control
mice. The growth plate zones were also not visually affected upon cartilage-specific
GSK-3β deletion (Fig 2.4 G).

2.3.5

GSK-3 inhibition increases chondrocyte proliferation

To determine why ex vivo inhibition of GSK-3 effects bone growth whereas in vivo GSK3β deletion had no observable effect, the cellular mechanisms controlling growth plate
dynamics were explored. Since the rate at which chondrocytes cycle through the growth
plate stages determines both zone morphology and bone growth, chondrocyte
proliferation was assessed through IHC analyses using Proliferating Cell Nuclear Antigen
(PCNA) antibodies (Fig 2.5). The PCNA IHC was quantified as the fraction of positively
stained cells per total number of cells. GSK-3 inhibition (SB86) did increase the amount
of actively proliferating cells in the tibia organ culture almost twofold (Fig 2.5 A, B).
Proliferation was not significantly decreased below the control levels upon treatment with
the PI3K inhibitor (LY) while treatment with both inhibitors increased proliferation
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Figure 2.4 (12) - Cartilage-specific deletion of GSK-3β.
Cartilage-specific GSK-3β KO mice carrying 2 alleles of the floxed Gsk3b gene and
expressing cre recombinase under the control of the collagen II (Col2a1) promoter (KO)
were created and compared to the control littermates (Cont). (A) Western blot analyses
using GSK-3β antibodies conducted on growth plate (GP) protein extracts from new born
littermate mice of Gsk3bfl/fl cre+ (KO) and control (Gsk3bfl/fl cre- or Gsk3bfl/wt cre-) (Cont)
genotype.

(B) Densitometric quantification of GSK-3β protein in P0 growth plate

extracts. (C) IHC using GSK-3β antibodies on paraffin sections of P0 tibia. Black box
in top image indicates the location of the lower higher magnification images. (D) Western
blot analyses of GSK-3β protein in calvarial tissue (Calv). (E) Western blot analyses of
GSK-3β protein in heart, brain, and kidney protein samples of control (C) and knockout
mice (KO). (F) Tibia length (mm) measurements from P0 control and KO mice. (G)
Paraffin sections of P0 tibiae from control and KO mice stained with Safranin O. All
Western blot analyses used β–actin as a loading control. Quantification used t-test
analyses where significance was denoted with an asterisk (n > 3, *: p < 0.05).
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Figure 2.5 (13) - GSK-3 inhibition increases proliferation in organ culture while
GSK-3β deletion in cartilage has no effect on proliferation in vivo.
Proliferating Cell Nuclear Antigen (PCNA) was utilized to stain proliferating cells in
both tibia organ culture (OC) experiments and cartilage-specific GSK-3β KO mice. (A)
IHC analyses of PCNA on paraffin section of tibia organ cultures treated with GSK-3
inhibitor (10µM SB415286 (SB86)), PI3K inhibitor (10 µM LY 294002 (LY)), a
combination of both inhibitors (10µM SB415286 + 10 µM LY 294002 (SB86 + LY)), or
DMSO (Cont). (B) Quantification of the PCNA staining from (A) as percentage of
stained cells to total cells. Results were statistically compared using a one-way ANOVA
with a Tukey post-test analyses, significance is denoted by letter asterisks (n = 3, *: p <
0.05). (C) PCNA IHC analyses of P0 tibia from cartilage-specific GSK-3β KO mice
(KO) and control littermates (Cont). (D) PCNA staining quantified as fraction of positive
stained cells. Results were compared by t-test. (n = 3,*: p > 0.05)
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significantly over the LY treatment, similar to the effect of GSK-3 inhibition only (Fig
2.5 B). Similar data was obtained using BrdU labelling and detection (Data not shown).
In contrast, no difference in the fraction of PCNA-positive chondrocytes was observed
upon cartilage-specific GSK-3β deletion (Fig 2.5 C, D).

2.3.6

Prehypertrophic cell cycle exit increased upon GSK-3
inhibition

Hypertrophic chondrocyte differentiation is initiated by cell cycle exit, giving rise to
prehypertrophic chondrocytes (49, 50). The cyclin-dependent kinase inhibitor p57 is both
a marker of prehypertrophic chondrocytes and promotes cell cycle exit in the growth
plate (49-54). In tibia organ culture, inhibition of GSK-3 or dual treatments of GSK-3
and PI3K inhibitors greatly increased the zone of p57 protein expression in the prehypertrophic zone (Fig 2.6 A black arrows insets) while the addition of the PI3K inhibitor
did reduce this zone, although not statistically significantly (Fig 2.6 A, B). This p57
positive staining was localized to the cell nucleus in the prehypertrophic zone (Fig 2.6 A
far right inset). In cartilage-specific GSK-3β KO mice, p57 protein expression was
similar to that of control littermates (Fig 2.6 C), and quantification did not show any
significant change in the length of the p57-positive zone (data not shown).

2.3.7

β-catenin expression in prehypertrophic chondrocytes is
upregulated upon inhibition of GSK-3

Arguably the most studied downstream target of GSK-3 is the transcription factor βcatenin, a target of the canonical Wnt pathway that is a central regulator of skeletal
development (7, 55-59). An increase in the amount to β-catenin protein was observed
specifically throughout the prehypertrophic/hypertrophic zone of tibiae in organ culture
treated with the GSK-3 inhibitor (Fig 2.7 A). IHC for β-catenin was also performed on
the other two treatments discussed above, LY and SB86+LY, however PI3K inhibition
yielded no change and dual inhibition results were inconclusive (data not shown).
Western Blot showed no significant change in β-catenin protein levels in the growth plate
of cartilage-specific GSK-3β KO mice, although levels consistently appeared increased in

65

66

Figure 2.6 (14) - GSK-3 regulates p57 expression in the prehypertrophic zone in
vitro while cartilage-specific GSK-3β deletion does not affect p57 expression in vivo.
(A) IHC analyses of p57 expression in paraffin sections of tibia organ culture treated with
GSK-3 inhibitor (10 µM SB415286 (SB86)), PI3K inhibitor (10 µM LY 294002 (LY)), a
combination of both inhibitors (10µM SB415286 + 10 µM LY 294002 (SB86 + LY)), or
DMSO (Cont). Black boxed insets are higher magnification images depicting the zones
of p57 staining, black arrows. Far right image is a higher magnification (boxed area) of
staining to determine cellular localization. (B) Quantification of the length (µm) of the
zone of p57 staining observed in (A). Data was analyzed by one-way ANOVA with a
Tukey post-test with significance denoted by asterisk (n > 3, *: p < 0.01). (C) IHC
analysis of p57 expression in paraffin sections of P0 tibiae of cartilage-specific GSK-3β
KO mice compared to littermate controls (Cont).
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Figure 2.7 (15) GSK-3β regulates β–catenin expression in the prehypertrophic zone.
(A) Sections of tibia organ cultures treated with a GSK-3 inhibitor (10µM SB415286
(SB86)) or DMSO (Cont) were analyzed by IHC using β–catenin antibodies. Black
brackets indicate the zone of β-catenin stained cells in the prehypertrophic zone. (B)
Western blot analyses of P0 growth plate protein extracts from cartilage-specific GSK-3β
KO mice (KO) and control (Cont) littermates probed with β–catenin antibodies, with βactin (Actin) as loading control. (C) Localization of β–catenin protein was conducted by
IHC using β–catenin antibodies on paraffin tibia sections from mice described in (B).
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mutant cartilage (Fig 2.7 B). However, IHC suggested that β-catenin levels are increased
is specific subsets of chondrocytes in cartilage-specific GSK-3β KO mice, in particular
prehypertrophic chondrocytes and the articular surface (Fig 2.7 C).

2.3.8

Upregulation of GSK-3α protein in response to GSK-3β
deletion in vivo

The two forms of GSK-3, α and β, play both overlapping and distinct roles (16, 17, 28,
29, 31). GSK-3α levels and overall phosphorylation of the GSK-3 proteins were
examined to understand the apparent lack of phenotype in the cartilage-specific GSK-3β
KO mice (Fig 2.8). Surprisingly, Western blotting demonstrated an approximately twofold increase in GSK-3α protein in KO cartilage (Fig 2.8 A, B). IHC further supported
these data by showing an increase in GSK-3α protein throughout the pre-hypertrophic
and hypertrophic area as well as the resting zone and articular surface (Fig 2.8 C). To a
lesser extent an increase in GSK-3α protein was observed in the proliferating zone (Fig 8
C). There was no obvious change in the total phosphorylation of the GSK-3 proteins in
all zones (Fig 2.8 D), providing further evidence that upregulation of GSK-3α
compensates for the loss of GSK-3β in cartilage.

2.4 Discussion
This study contributes important and novel data to our understanding of both skeletal
development and GSK-3 signaling. Our results demonstrate profound effects of GSK-3
inhibition on bone growth in a tibia organ culture system, which is contrasted by minimal
phenotypes observed upon cartilage-specific deletion of GSK-3β. This absence of
phenotype is likely due to compensatory upregulation of GSK-3α expression, a
mechanism that has, to our knowledge, not been reported for any other tissue or context.
Our tibia organ culture experiments show that inhibition of GSK-3 results in increased
longitudinal growth of endochondral bones. This was likely caused, at least in part, by
increased proliferation of chondrocytes in the resting and proliferating zones. The
shortened hypertrophic zone resulting from GSK-3 inhibition appears to be
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Figure 2.7 (16) - In vivo deletion of GSK-3β causes upregulation of GSK-3α protein
in chondrocytes.
(A) Western blot analyses of GSK-3α protein in growth plate protein extracts of
cartilage-specific GSK-3β KO and control mice, with β-actin as loading control. (B)
Densitometric quantification of GSK-3α Western blot analyses (A); statistical analysis
was conducted using t-test, significance is indicated by asterisk (*) (n = 3, *: p < 0.05).
(C) IHC analyses using GSK-3α antibodies on paraffin sections of PO KO and control
tibiae. (D) IHC analysis using antibodies detecting the phosphorylated state of both
GSK-3 forms, α and β.
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counterintuitive to the increase in growth observed by us. However, the larger proportion
of PCNA-labelled chondrocytes, the increase in p57 staining and the relative increase in
the length of the mineralized zone all suggest that all processes in the growth plate
(proliferation, differentiation and replacement of cartilage by bone) occur at a faster rate
upon GSK-3 inhibition, thus resulting in increased bone growth. The reduced length of
the hypertrophic zone would therefore not be due to delayed differentiation, but rather to
faster turnover of hypertrophic cartilage to bone.
Our observations of increased chondrocyte proliferation and accelerated bone maturation
in response to GSK-3 inhibition are opposite to findings from Naski and colleagues who
showed that a different pharmacological GSK-3 inhibitor reduced chondrocyte
proliferation and differentiation in a metatarsal organ culture system (60). These
differences might be due to the nature and/or concentration of the inhibitors, the duration
of treatment or the identity of the skeletal elements investigated, suggesting that the
effects of GSK-3 in cartilage might be context-dependent. However, our data showing
that GSK3 inhibition promotes endochondral bone growth – which is unlikely to occur
when both proliferation and hypertrophy of chondrocytes are inhibited – are supported by
a recent in vivo study where loss of one allele of the Gsk3b gene rescues the dwarfism of
mice deficient for cGMP-dependent kinase II (cGKII), another upstream inhibitor of
GSK-3 (24). cGKII is a key mediator of the anabolic effects of C-type natriuretic peptide
on endochondral bone growth (61). These data by Kawasaki et al. (24) show that
inhibition of GSK-3 activity is required for the anabolic effects of cGKII in bone, an
effect we mimic by pharmacological inhibition of GSK-3.
Our data also provide insights into the relationship between PI3K and GSK-3 signaling in
cartilage. PI3K inhibition resulted in decreased phosphorylation (indicating increased
activity) of GSK-3. In agreement with these data, pharmacological inhibition of GSK-3
rescued many of the effects of the PI3K inhibitor, in particular on bone growth. However,
this was not true for the length of the hypertrophic zone, which was reduced by both
inhibitors individually or in combination. However, these effects on the hypertrophic
zone could be due to the different mechanisms, since PI3K inhibition appears to delay
chondrocyte hypertrophy and the associated bone growth ((15) (reviewed in 62)), while
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our data presented here suggest that GSK-3 inhibition accelerates the replacement of
hypertrophic cartilage by mineralized tissue. Furthermore, the similar effects of both
inhibitors on the hypertrophic zone reflect the fact that PI3K also acts through other
downstream effectors in addition to GSK-3 (63), while GSK-3 is also involved in the
response to signals not mediated by PI3K, such as Wnts.
Given the significant impact of GSK-3 inhibition in organ culture, the absence of a clear
phenotype in cartilage-specific Gsk3b KO mice was surprising. However, our subsequent
molecular analyses revealed the putative explanation. First, the expression of GSK-3β in
cartilage is quite restricted, at least in comparison to the more ubiquitously expressed
GSK-3α. These different expression patterns were also shown at the mRNA level in our
earlier microarray studies on microdissected mouse growth plates (64). More importantly,
GSK-3α expression was upregulated markedly in all zones of the growth plates of
Gsk3b-mutant mice, even where very low levels of GSK-3β were seen in wild type mice
(such as in the proliferative zone). These data suggest that GSK-3α is able to compensate
for most functions of GSK-3β in chondrocytes. However, our results cannot exclude
alternative explanations for the lack of a phenotype in our KO mice; analyses of double
KO mice for both Gsk3 genes will be required to firmly establish redundant functions of
these two genes.
The molecular basis of the increase in GSK-3α levels in our mutants is currently
unknown. Since GSK-3β regulates the stability of many other proteins (65), it is tempting
to speculate that loss of GSK-3β leads to stabilization of GSK-3α protein. However, to
our knowledge no such cross-talk between the two GSK-3 proteins has been described.
Alternatively, it is plausible that increased GSK-3α expression in our KO mice is due to
increased transcription, mRNA stability and/or translation. Future studies will need to
address the mechanisms involved.
The one exception to compensation appeared to be upregulation of β-catenin protein
levels in specific chondrocytes of cartilage-specific Gsk3b KO mice, suggesting that
GSK-3α is not able to fully substitute for GSK-3β function in all chondrocytes. Since this
effect was only seen in a few chondrocytes, it was not reflected in Western blot analyses
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of extracts from the entire cartilage, but it was very reproducible in immunohistochemical
analyses of tissue sections. Notably, increased staining for β-catenin in mutant mice was
seen in exactly those cells that express detectable levels of GSK-3β in wild type mice
(e.g. articular and prehypertrophic/hypertrophic chondrocytes), suggesting that GSK-3α
can not fully compensate for this aspect of GSK-3β function in these cells. The reason for
this inability is unclear, but might be related to the particular levels of expression of the
two GSK-3 proteins in specific chondrocyte populations. Analyses of double mutants for
both Gsk3 genes will provide further insight into this unexpected finding.

While

chondrocyte function is very sensitive to both supra- and superphysiological levels of βcatenin (56, 57), the moderate change in expression observed here appears to be
insufficient to induce changes in cartilage development and bone growth, at least over the
time frame evaluated here. It will be interesting to examine in the future whether
increased β-catenin or other aspects of cartilage-specific loss of GSK-3β alters the
susceptibility to cartilage degeneration in osteoarthritis.
In closing, we believe that this study contributes important and novel information to our
understanding of the complicated relationship between the two GSK-3 proteins as well as
to our understanding of the signaling pathways controlling endochondral bone
development. Additional studies, such as the simultaneous inactivation of both Gsk3
genes in cartilage, will further elucidate the role of these key signaling molecules in the
physiology and pathophysiology of cartilage.
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Chapter 3

3

Skeletal-specific deletion of Glycogen Synthase Kinase 3
beta (GSK-3β) delays postnatal growth and skeletal
development

A version of this article was submitted for publication as an original research article:
Gillespie JR, Beaucage KL, Dupuis H, Wong SY, Pollmann SI, Holdsworth DW, Kream
B, DiMattia G, Patel S, Woodgett JR, Beier F. Skeletal-specific deletion of Glycogen
Synthase Kinase 3 beta (GSK-3β) delays postnatal growth and skeletal development.
Submitted to JBMR December 2011.
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3.1 Introduction
The bones of the skeleton are formed through two different processes, endochondral and
intramembranous ossification (reviewed in (1-3)). Most of the skeleton forms through
endochondral ossification in which a cartilage scaffold is produced by chondrocytes
before it is converted to bone, produced by osteoblasts. Growth plate chondrocytes are
found at either end of long bones and arranged in distinct layers of resting, proliferating
and hypertrophic cells, differing in gene expression patterns, rate of cell cycle
progression, and cell morphology (reviewed in (3-6)). Surrounding the growth plate is the
perichondrium, containing pre-osteoblasts that differentiate into mature osteoblasts to
form the bone collar or cortical bone through intramembranous ossification (reviewed in
(7,8)). Intramembranous ossification also forms the calvariae of the skull and occurs
when bone is formed without a cartilage template. Thus, the skeleton is a large and
complex component of the body requiring precise autocrine, paracrine and endocrine
signaling to form properly.
Glycogen Synthase Kinase-3 (GSK-3) is an ubiquitous cellular regulator that functions as
a “brake” on many anabolic pathways, such as the Wnt/β-catenin and insulin-activated
pathways. GSK-3 is an unusual protein kinase due to its high level of activity in resting
tissues, its inhibition upon cellular stimulation, and its role as a negative regulator of the
activity of many substrates. Mammals have two GSK-3 genes that encode GSK-3α and
GSK-3β with molecular masses of 51kDa and 47kDa, respectively (reviewed in (7-9)).
Inhibition of GSK-3α and β can occur through at least two mechanisms: direct
phosphorylation (Ser21 and Ser9 of GSK-3α and β, respectively) as occurs through the
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insulin/phosphatidylinositide 3-kinase (PI3K)/AKT signaling pathway (10), or through
disruption/sequestration of the protein complex involved in canonical Wnt/β-catenin
signaling (9).

The specific roles of GSK-3α and/or β in regulation of the various

signaling pathways is unclear since they appear functionally redundant in some studies
(11,12), but differential and tissue-specific roles for the two forms have also been
demonstrated (13-17). Moreover, the relative roles of GSK-3 can be dependent on the
genetic background or strain of mice examined (18).
Other groups have studied the phenotypic consequences of manipulating Gsk3b
expression on the skeleton (19-21). Germline homozygous deletion of Gsk3b causes a
variable phenotype depending on genetic background and can result in embryonic
lethality (19) or survival to P0 with cleft palate, bifid sternum and delayed ossification of
the sternum, skull, ear bones, and cranial base (20). In contrast, heterozygous deletion of
Gsk3b caused increased ossification, clavicle abnormalities and increased bone resorption
(21).

It would appear that these opposing skeletal phenotypes (e.g. delayed versus

increased ossification) are Gsk3b dosage-dependent effects; however, all these
phenotypes are based on germline loss of Gsk3b. Consequently, it is unclear whether
these skeletal phenotypes are cell- or tissue-autonomous.
We previously generated mice in which GSK-3β was specifically deleted in chondrocytes
and compared their in vivo phenotype with the effects of pharmacological inhibitors of
GSK-3 on ex vivo tibia organ cultures (22).

The ex vivo studies demonstrated that

inhibition of GSK-3 (both α and β) increased bone growth. However, the characterization
of cartilage-specific GSK-3β deficient mice did not reveal any phenotype with the
exception of an increase in GSK-3α protein expression. This lack of phenotype could
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have been due to compensation by GSK-3α; however, these observations suggest that
skeletal phenotypes in the global GSK-3β KO mice (20) are likely due to functions of
GSK-3β in other skeletal lineages such as osteoblasts. To address this possibility, we
created mice in which GSK-3β was inactivated in early differentiating skeletal cells and
osteoblasts.

3.2 Materials and methods
3.2.1

Materials

The following antibodies were utilized in this study: Cre ab24608, Sox9 ab3697 (Abcam,
Cambridge, MA); actin A5441, Runx2 R9403 (Sigma Chemical Co., St. Louis, MO);
goat anti-rabbit hrp sc-2004, donkey anti-goat hrp sc-2020, goat anti-mouse hrp sc-2005,
Rankl sc-9072, p57/Kipp2 sc-8298 (Santa Cruz Biotechnology, Santa Cruz, CA); GSK3β #9315, pGSK-3β #9336, GSK-3α #9338, PCNA #2586, cleaved caspase 3 #9661, βcatenin #9562 (Cell Signaling Technology, Danvers, MA). General chemicals and
supplies were purchased from Sigma and VWR (Radnor, PA), organ culture reagents
were from Invitrogen (Carlsbad, CA).

3.2.2

Mouse breeding and genotyping

Mice homozygous for floxed Gsk3b alleles (Gsk3bfl/fl) have been described previously
(17,22-24) and were crossed with mice expressing cre recombinase under the control of
an osteoblast-specific 3.6kb fragment of the rat Col1a1 promoter (25,26). Male mice
heterozygous for the floxed Gsk3b allele and expressing cre under control of the 3.6 kb
Col1a1 promoter were backcrossed with homozygous Gsk3b floxed female mice. The
offspring from these crosses were analyzed. Mice were exposed to a 12 hr light-dark
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cycle and fed tap water and regular chow ad libitum. All procedures involving animals
were approved by the University of Western Ontario Animal Care and Use Committee.
PCR genotyping was performed from ear notch DNA using primers 5’GGGGCAACCTTAATTTCATT-3’

(forward)

and

5’-

TCTGGGCTATAGCTATCTAGTAACG-3’ (reverse) for GSK-3β for 30 cycles of 96 οC
55sec, 56.5οC 45 sec, 68 οC 2:45min to amplify. The cre transgene was detected using the
primers

5’-CACACTGTGTAGTGCTTCGT-3’

(forward)

and

5’-

CCTCCAAACCATCCAAGAT-3’ (reverse) using 40 cycles of 95 οC 45sec, 58 οC 30sec,
72 οC 1min. Cartilage-specific KO mice were bred and analyzed as described (22).

3.2.3

Skeletal staining

Skeletal staining was performed as described previously (22,24,27,28). Briefly, the skin
and organs were removed and the resulting skeletal preparation was dehydrated in 95%
ethanol for 24 hours, followed by acetone for 24 hours. Skeletons were stained with
0.015% Alcian blue, 0.05% alizarin red and 5% acetic acid in 70% ethanol. The length
of staining depended on the age of specimen when harvested, and was up to 4 days for
21-day-old mice. Skeletons were cleared in 2% KOH overnight, 1% KOH for several
days and 0.5% KOH for approximately 1 week (varying with age of specimen). The
stained skeletons were stored in glycerol/ethanol (1:1). Images were captured with a
Nikon SMZ1500 dissecting microscope with a Photometrics Coolsnap camera using
ImageMaster 5.0 software. At least 3 independent littermate pairs (control and knockout)
were examined per time point. Representative examples of each skeletal abnormality are
shown.
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3.2.4

Histology and immunohistochemistry (IHC)

Freshly dissected tibia from both P0 and P21 mice were fixed in 4% paraformaldehyde
overnight and decalcified with 0.1M EDTA/PBS at room temperature before embedding
and sectioning at the Robarts Research Institute Molecular Pathology Core Facility
(London, ON). 5µm sections were dewaxed in xylene followed by a graded series of
alcohol washes, 100% x2, 95% x1, 70% x1. Sections were stained with either Picrosirius
Red, Safranin O/Fast green, or Von Kossa/Toluidine blue. Measurements of trabecular
length from the hypertrophic/bone interface to the average end of the trabecular bone in
the middle of the tibia section were performed using Qcapture software. IHC sections
were incubated in 3% H2O2 for 15 min at room temperature, followed by incubation in 10
mM sodium citrate at 95 οC for 30 min and blocking with 5% goat serum in PBS (27-30).
Sections were incubated with primary antibody overnight at 4 οC, washed 4 times in PBS,
and secondary antibody was applied according to manufacturers’ recommendations. For
detection, DAB substrate was used and counterstained with methyl blue. All images
were taken with a Leica DME microscope with a Qimaging Micropublisher 5.0 RTV
camera using QCapture Pro 5.1 software.
Alternatively, bones were not decalcified and shipped to The Centre for Bone and
Periodontal Research (Montreal, QC, Canada) for plastic embedding, sectioning (5µm)
and staining with Von Kossa/Toluidine Blue.
Sections were examined using kits for TUNEL (Calbiochem) and TRAP (Sigma), as per
manufacturers’ instructions with minor optimizations. TRAP staining was performed
overnight at 4 οC. Representative stains, IHC, and labelling from at least three
independent pairs of littermates are shown.
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3.2.5

Western blot analyses

Fresh calvaria and cartilage from long bones were dissected from P0 mice in cold Puck’s
solution A (PSA) (22,24,27,31). Samples were flash frozen in RIPA buffer and stored at
-20 οC overnight, then homogenized, sonicated and centrifuged.

After total protein

content was determined, 25-35µg total protein was loaded per lane into precast NuPAGE
Novex Midi Tris-Acetate Gels and separated using the XCell Surelock Mini-cell
(Invitrogen) system. Gels were blotted using XCell II Blot Module (Invitrogen) as per
manufacturer’s instructions. Blots were blocked in 5% BSA TBST solution for 1 hour,
and then probed with primary antibody overnight at 4 οC.

Appropriate secondary

antibody (HRP-conjugated) was incubated for one hour at room temperature, and the
resultant signal was detected using the ECL detection system (Amersham).
Representative blots from at least 3 independent pairs of littermates are shown.
Quantitative densitometry analysis was conducted using a ChemiImager 5500 system
subtracting background and normalizing to the β-actin loading control signal.
Densitometry results were converted relative to control, allowing comparison between
blots by t-test analysis.

3.2.6

Serum analysis

Serum readings were performed using a Millipore Multiplex system for OPG (Cat No.
MBN1A-41K), Rankl (Cat No. MBN-41K-1RANKL), IGF-1 (Cat No. RMIGF187K),
and GH (Cat No. EZRMGH) in the Screening Lab for Immune Disorders, St Joseph
Hospital, London, Ontario, Canada.
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3.2.7
3.2.7.1

Micro-CT
Image acquisition

Images of isolated p21 humeri were acquired using a micro-computed tomography
(micro-CT) system (eXplore Locus SP, GE Healthcare Biosciences, London, Ontario,
Canada). The scanning protocol included 900 views acquired over 2.5 hours, using an xray tube potential of 80kVp and tube current of 80 µA. Images were reconstructed with
an isotropic resolution of 26 µm. In addition to the specimen scans, a separate calibration
phantom containing air, water and hydroxyapatite mimic (SB3, Gammex RMI,
Middleton, WI, USA) was scanned and used to convert the original reconstructions into
Hounsfield Units.

3.2.7.2

Cortical bone analyses

Cortical bone analyses was performed using microCT images of humeri using
MicroView software. A mid-diaphyseal defined volume of interest (VOI) (1.7 mm x 1.7
mm x 0.2 mm) was defined by limiting the VOI to the appearance of the distal end of the
deltoid tuberosity. Quantification of cortical analyses for BMD (mg/cc) and cortical
thickness (mm) were performed on each sample using the Advanced Bone Analyses
Application in the MicroView software.

3.2.7.3

Trabecular bone analyses

Trabecular bone analyses was performed using microCT images of humeri using
MicroView software. The VOI (0.8 mm x 0.9 mm x 0.7 mm) was proximally limited to
the appearance of the growth plate in the proximal humeri. The VOI was positioned in
the middle of the metaphysis, in order to maximize trabecular bone, while excluding
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cortical bone from the analyses. Quantification of trabecular analyses for BV/TV (%),
connectivity (1/mm3) and trabecular spacing (mm) were performed using the Advanced
Bone Analyses Application in the MicroView software.

3.2.8

Statistical analysis

All data were collected from at least 3 independent pairs of littermates. Data was
expressed as mean ±SEM, and p values under 0.05 were considered significant. For
general measurements, statistical significance was determined by t-test analysis
comparing control to KO littermates using GraphPad Prism 3.00 for Windows. Western
blot densitometry data were normalized to controls and compared by t-test. Comparison
of multiple measurements was performed using one-way Anova and a Tukey post test.

3.3 Results
3.3.1

Col1a1-driven Gsk3b inactivation

To study the roles of Gsk3b in skeletal development, we crossed mice with floxed alleles
of GSK-3β (Gsk3bfl/fl)(17,22-24) with mice expressing cre recombinase under control of
the 3.6kb fragment of the rat Col1a1 promoter (25,26). The following nomenclature is
used throughout this paper for the genotype of the mice: Gsk3b+/fl cre- and Gsk3bfl/fl cre- referred to as control (Cont), Gsk3bfl/+cre+ - referred to as heterozygote (Het), and
Gsk3bfl/fl cre+ - referred to as knockout (KO). Recombination was detected in DNA
extracted from Het and KO mice using PCR (Fig. 3.1A).
Western blot analyses revealed that cre protein was expressed at high levels in KO
calvarial tissue (bone) and to a lesser extent in growth plate cartilage of P0 KO mice (Fig.
3.2A). Cre protein was not detectable by Western blot in other tissues of KO mice,
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Figure 3.1 (17) - Effective recombination
PCR with GSK-3β (Top) and cre (bottom) primers. GSK-3β primers show floxed (fl), wildtype
(wt) and recombinant (rec) alleles. The cre primers indicate which mice are cre positive.
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including heart (Fig. 3.2A), brain, skin and liver (data not shown). To further examine the
skeletal tissue specificity of cre expression, immunohistochemistry (IHC) was performed
on P0 tibia sections (Fig. 3.2A).

As expected, cre protein was detected in the

perichondrium and in cells surrounding the trabeculae. Slight staining for cre was also
seen by IHC in prehypertrophic/hypertrophic cartilage. Next, GSK-3β protein expression
was examined to determine if Cre expression corresponds to loss of GSK-3β protein (Fig.
3.2B). Quantitative densitometry of Western blots demonstrated that calvarial GSK-3β
protein levels were reduced by 70%. This loss of GSK-3β in bone cells was confirmed by
IHC (Fig. 3.2B). GSK-3β protein was also reduced in cartilage, to 55% of control,
specifically in late hypertrophic chondrocytes as shown by IHC (Fig. 3.2B).
To determine if the ablation of GSK-3β protein would affect the phosphorylation and
therefore activity of remaining GSK-3β, the levels of phosphorylation was examined
(Fig. 3.2C). The amount of phosphorylated (inactive) GSK-3β was reduced in both KO
calvariae (to 43% of control) and cartilage (to 62% of control) samples. ColI-GSK3β-/mice showed an increase in GSK-3α protein expression in cartilage, whereas GSK-3α
was almost undetectable in bone lysates compared to GSK-3β and cartilage samples (Fig.
3.2D). Elevated GSK-3α in mutant cartilage was confirmed by IHC analyses. These
results suggest that GSK-3β ablation causes a tissue- and differentiation stage-specific
upregulation of GSK-3α protein in growth plate cartilage, in agreement with our earlier
study (22), but not in bone tissue.
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Figure 3.2 (18) – Bone-specific inactivation of the Gsk3b gene
(A) Analyses of cre protein expression in skeletal tissue. Top: Western blot analyses of
newborn (P0) protein extracts with cre antibody (loading control β-actin) for control
(Gsk3bfl/fl cre- or Gsk3bfl/+ cre- , C) and KO (Gsk3bfl/fl cre+; K) mice, using heart (Hr),
cartilage (Cart) and calvariae (Calv) lysates. Bottom: IHC of P0 tibiae shows that cre
protein is present in perichondrium (P), in trabecular (T), prehypertrophic chondrocytes
(PH) and cortical bone (C).
(B) GSK-3β protein expression in cartilage and bone tissue. Top: Western blot analyses
of P0 samples with GSK-3β antibodies and quantitative densitometry results below of
cartilage (n=8) (left) and calvaria (n=8) (right) samples. Bottom: IHC of P0 tibia
sections probed with GSK-3β antibody.
(C) Analyses of phosphorylation levels of GSK-3β protein. Top: Western blot analysis
and Bottom: Densitometric quantification of the amount of pGSK-3β in control (C or
Cont) or bone specific KO (K or KO) mice, in cartilage (n=4) (left) and calvaria (n=4)
(right).
(D) Analyses of GSK-3α protein levels in skeleton of bone-specific GSK-3β KO mice.
Left: Densitometry of GSK-3α protein expression from Western blot analyses of tissue
samples of cartilage (n=8) and calvariae (n=8) from control (Cont) and knockout (KO)
mice (loading control β-actin). Right: IHC conducted on P0 tibia section using GSK-3α
antibodies, with the pre-hypertrophic/hypertrophic growth plate zone displayed.
Quantitative data were compared using t-test analysis, significant differences are denoted
by asterisk (*: p < 0.05).
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3.3.2

Decreased weight, delayed postnatal bone growth, and altered
growth plate morphology in mutant mice

The number of KO mice born was slightly higher than the expected Mendelian ratio (47
KO mice out of 154 total mice), demonstrating that KO mice are viable at birth. Of the
154 pups born, 17 died on the day of birth (P0), and 13 of these were KO mice. Of the 4
control mice that died, 3 were victims of parental infanticide and the fourth died for
reasons unknown. The KO mice that died were born alive and died within the first 12
hours. There was no obvious abnormality associated with the deaths; the pups fed and
did not appear to suffer from respiratory distress.
Surviving KO mice were significantly (11%) lighter than their control littermates at P0
(Fig. 3.3A). This difference in weight increased to about 26% by P10 and remained
relatively consistent (27%) by P21 (Fig. 3.3A). There was no significant difference in
weight between heterozygous and control mice (Fig. 3.3A). The greatest effect on KO
animal weight occurred between birth and P10, and there was no sex-specific difference
in the weight amongst the genotypes (data not shown).
We next examined the length of endochondral bones. There was no significant difference
between control and KO tibia length at P0; however, by P21 KO tibiae were
approximately 15% shorter (Fig. 3.3B). Thus, the decrease in animal weight preceded the
reduction in bone growth and was much greater than the decrease in skeletal length (27%
vs. 15%). We evaluated serum levels of insulin-like growth factor 1 (IGF1) and growth
hormone (GH) in weaned mice to determine whether reduced growth was associated with
changes in these hormones.

However, both IGF1 and GH were unchanged in the

skeletal-specific KO mice (Fig. 3.4).
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The observed reduction of GSK-3β protein in growth plate cartilage in mutant mice (Fig.
3.2B) along with the decreased bone length (Fig. 3.3B) prompted us to examine the
organization of the growth plate in KO mice. The growth plates of P0 KO mice showed
similar overall organization relative to control growth plates (Fig. 3.3C). Upon closer
inspection of the growth plate zones, subtle phenotypes emerged (Fig. 3.3C). The cells of
the resting zone appeared larger with more cytoplasmic area in KO animals (Fig. 3.3C r),
potentially indicating earlier onset of chondrocyte hypertrophy in areas of future
secondary ossification. The proliferating zone of KO mice appeared to be hypercellular,
possibly indicating increased proliferation, and the cells appeared flatter (Fig. 3.3C p).
The growth plate length from the articular surface to the trabecular bone was not
significantly different between P0 KO and control mice. However, when the individual
zones of the growth plate were measured, a significant increase in the length of the
hypertrophic zone of KO mice was discovered (Fig. 3.3C h, graph). There were no
significant differences in the length of proliferating and resting zones.

Similar

phenotypes were seen in the femur (data not shown).
To determine whether the growth plate phenotype seen in the P0 mice would persist, we
examined P21 growth plates (Fig. 3.3D). There was a significant increase in total growth
plate length in KO mice (Fig. 3.3D): however, the hypertrophic zone in the KO animals
was no longer significantly longer than that of control littermates.

3.3.3

Delayed skeletal development and ossification in KO mice

Skeletal malformations (e.g. of palate and sternum) have been previously observed in
global GSK-3β knockout mice (20). We examined our KO model for a similar skeletal
phenotype. P0 skeletons were stained with Alizarin Red (bone) and Alcian Blue
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Figure 3.3 (19) – Reduced weight and growth plate changes on KO mice
(A) Comparison of postnatal mouse body weight. Weights of control (Cont),
heterozygous (Het) and knockout mice (KO) were compared at P0 (n=8) (left), P10,
(n=13) (middle) and P21(n=11) (right).
(B) Lengths of tibiae were compared at P0 (n=13) (top) and P21 (n=4) (bottom).
(C) (Top) Safranin O Stain staining of sections, with cartilage glycosaminoglycans
stained red. (GP – growth plate; r – resting zone; p – proliferating zone; h – hypertrophic
zone) (bottom) Higher magnification of growth plate zones, with the same orientation as
in A (articular surface [art] at top and trabecular bone [trab] at bottom). (bottom right)
Length of hypertrophic (h) zone at P0. Statistical analysis was conducted using paired
(littermates) t-test (n=6).
(D) (Left) Comparison using Von Kossa/Toluidine blue staining of P21 tibia growth
plates, cartilage stained in purple and mineralized tissue in black. The orientation is
displayed on right of control figure, with secondary ossification center (2nd oss) on top
and trabecular bone (trab) at bottom. (right) Length of P21 growth plate. Statistical
analysis was conducted using a paired t-test (sex matched littermates) (n=3).
Quantitative data were compared using t-test analysis, significant differences are denoted
by asterisk (*: p < 0.05).
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Figure 3.4 (20) – Serum IGF and GH
IGF and GH serum levels for weaned mice.
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(cartilage) (Fig. 3.5, Fig. 3.6A,B). Our KO mice demonstrated delayed hard palate
closure and bifid sternum (Fig. 3.5A), although these defects were not as severe as those
described previously in the global GSK-3β KO mice (20). There were no observable
differences in the palate of KO mice compared to controls at P21, suggesting a
developmental delay rather than a block in development (data not shown). The delay in
hard palate closure did not affect the soft palate and mice appeared to feed normally. At
P21 the KO sternum was no longer bifid; however, the mineralization of the Xiphoid
process seen in the control mice was absent in the KO littermate (Fig. 3.5A, circled).
Several previously undescribed skeletal phenotypes were also evident at P21. Limbs
appeared morphologically normal (but slightly shorter) with the exception of the deltoid
tuberosity that was clearly underdeveloped and more rounded in KO mice (Fig. 3.5B).
The deltoid tuberosity forms through endochondral bone formation involving interaction
between tendon and cartilage (32). Further studies showed that the deltoid tuberosity is
already smaller at P0 (Fig. 3.5B) and remained underdeveloped even at 1 year of age
(data not shown). Postnatal ossified structures of the knee joint such as the patella and
sesamoid bones were much smaller in mutant mice (Fig. 3.5C, circled). Delayed KO
pelvic bone closure was also observed at P21 that involves the conversion of cartilage to
bone (Fig. 3.5D, circled). KO P21 vertebrae were underdeveloped and failed to fuse (Fig.
3.5E, P0 Fig. 3.6A). The most obvious defect was the absence of the large spinous
process of the T2 vertebrae (Fig. 3.5D left).

Other apparent closure failures were

observed in the KO vertebrae associated with the false and floating ribs, as shown for
T10 and T13 (Fig. 3.5D). Most other vertebrae appeared normal and closed but had
underdeveloped spinous processes (data not shown). Thus, KO mice displayed numerous
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Figure 3.5 (21) – Delayed skeletal development and ossification on KO mice
Panels A-E show Alizarin Red (Bone) and Alcian Blue (Cartilage) staining of skeletal
elements, comparing Control (Cont) and skeleton-specific GSK-3β knockout mice (KO):
(A) P0 hard palate (top left) P0 Sternum (Top right) , (Bottom) P21 circled Xyphoid
process
(B), Deltoid tuberosity, (Top) P0, (Bottom) P21
(C) knee joint , (Top) P0, (Bottom) P21
(D) pelvic bone , (Top) P0, (Bottom) P21
(E) T2 vertebrae (left), T10 vertebrae (middle), T13 vertebrae (right).
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Figure 3.6 (22) – P0 delayed skeletal development
(A) P0 vertebrae demonstrating wider gap between ossified elements
(B) P0 skulls illustrating larger space between the lambdoid and sagittal sutures
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examples of delayed development and ossification of postnatal skeletal elements formed
through endochondral ossification.

3.3.4

Suture closure and strength as well as snout length are altered in
KO mice

We next inquired whether intramembranous bones were also affected by deletion of
osteoblast GSK-3β. Calvarial bones of the skull are formed through intramembranous
ossification and defects are often seen as suture malformations where the flat bones meet.
Measurements of the skull and calvaria/suture length (diagrammed Fig. 3.7A, left)
indicated that the skulls of KO mice were 10% shorter than controls at P21 (Fig. 3.7A).
However, the sagittal and frontal sutures were not significantly shorter, indicating that a
shorter snout (nasal suture; 17% shorter) was the main reason for the decreased skull
length in the KO mice (Fig. 3.7A).
At P21 a delay in cranial suture closure was observed; the occipital and lambdoid sutures
are displayed in Fig. 3.7B as examples, but similar phenotypes were observed for sagittal
and frontal sutures at P0 (Fig. 3.6B). The strength of the sutures was noticeably reduced
in KO mice since during tissue processing (when solution is changed from low to high
osmolarity) the suture failed (opened) at a much higher frequency than occurred for
control littermates. Long-term studies confirmed weaker sutures in the KO mice as even
at one year of age (where no sutures from control mice failed during processing), KO
sutures still separated frequently (Fig. 3.7C). The pattern of the sutures was also
noticeably altered in KO mice which displayed less interdigitated sutures, an indicator of
reduced suture strength (33-36), as displayed in the lambdoid suture tracing in Fig. 3.7C.
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P21 KO mice also showed an altered suture pattern in the anterior frontal suture (Fig.
3.7D) as it was split into two with bone in the middle whereas control mice display the
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Figure 3.7 (23) – Delayed suture closure in KO mice
(A) Examination of calvarial sutures using Alizarin Red (Bone) and Alcian Blue
(Cartilage) staining. Right: Length measurements of the skull as shown by the red
arrows. Right Middle: Assessment of longitudinal length (nose to back of skull) of skull
sutures along the midline (n=4). Left Middle: Sutures length relative to control (n=4).
Left: Representative picture of the difference in the length of the nasal suture (or snout
length) between control and KO mice.
(B) Lateral view of a mouse skull comparing control (Cont) and KO mice showing
occipital (O) and lambdoid (L) sutures at P21.
(C) Analysis of sutures at 1 year of age. Right: Representative picture of suture failure in
1 year old KO mice, displaying sagittal (S) and lambdoid (L) sutures. Left: Analysis of
suture formation, showing lambdoid (L) suture near the sagittal (S) suture. Trace of
lambdoid suture is shown below the picture.
(D) Comparison of anterior frontal (AF) sutures of control and KO mice at P21. Higher
magnification is shown on the right with arrows indicating suture.
(E) Analysis of anterior frontal suture from 1year old mice. Trace of suture is displayed
on the right.
Quantitative data were compared using one-way ANOVA with a Bonferroni’s post-test
or by t-test analysis, significant differences are denoted by asterisk (*: p < 0.05).
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typical single suture. This phenotype was still present in the majority of the one-year-old
KO mice examined (Fig. 3.7E).
Most of P21 phenotypes described are present at P0 (Fig. 3.5), but less dramatic (Fig. 3.6)
or have not ossified at P0. By 1 year of age many of the delayed phenotypes have
“caught up” in terms of morphology, with the exception of the deltoid tuberosity that
remained rounded. Vertebrae appear fused and the T2 spinous process is present at that
age, but still smaller (data not shown).

3.3.5

Transiently increased bone formation in KO mice

We next examined the effects of Gsk3b deletion on trabecular bone formation. Collagen
production and bone formation/calcification was examined by Picrosirius red and Von
Kossa/Toluidine Blue staining of tibiae at P0 (Fig. 3.8A) and P21 (Fig. 3.8B). Picrosirius
red staining showed that the length of trabeculae was increased by almost 100% in KO
P0 mice (Fig. 3.8A). This data was confirmed with von Kossa-stained sections (data not
shown). The mid diaphysis of KO mice also displayed increased mineralized trabecular
bone (Fig. 3.8A, circled and transverse section). At P21, the increase in length of the
trabeculae was still significant although less dramatic (25%; Fig. 3.8B), but the mid
diaphysis trabecular phenotype was no longer apparent (data not shown). In agreement
with these data, microcomputed tomography (µCT) analyses of humeri revealed that at
P21 there were no significant changes in bone quality (Fig 3.8C), e.g., cortical thickness
and BMD (Fig. 3.9A), and trabecular bone volume/total volume, connectivity, and
spacing (Fig 3.9B). However, µCT analyses confirmed delayed development of the
deltoid tuberosity in mutant animals.
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Figure 3.8 (24) – Increased bone formation in KO mice
(A) Analyses of bone formation in P0 bone-specific GSK-3β KO mice. Top left: P0 tibia
stained with Picrosirius red for fibrillar collagen. Bottom left: Length of trabeculae
(Black arrows) (n=7). Increased mid diaphysis trabecular bone was observed in KO mice,
circled. Top right: VonKossa/Toluidine blue stain showing increased mid diaphysis
calcification. Bottom right: Comparison of P0 tibia transverse sections stained with Von
Kossa/Toluidine blue in the tibia mid diaphysis
(B) P21 tibia sections stained with Von Kossa/Toluidine blue showing longer trabeculae
in KO mice, marked with arrows (top) and quantified (n=4) (bottom).
(C) µCT analyses of P21 humeri. The deltoid tuberosity (DT) and growth plate (GP) are
indicated with arrows.
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Figure 3.9 (25) – Bone quality characterization
Microcomputed tomography (µCT) of P21 ColI-GSK-3β KO and control (Cont) mice
humeri
(A) Cortical bone characterization, thickness and BMD (n=4).
(B) Trabecular bone characterization, bone volume fraction (BV/TV), connectivity,
spacing (n=4).
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Figure 3.10 (26) – ColII-GSK-3β KO trabecular bone analysis
(A) Analyses of bone formation in P0 cartilage-specific GSK-3β KO mice. Top left: P0
tibia stained with Picrosirius red for fibrillar collagen. Bottom Middle: Length of
trabeculae (Black arrows) (n=5). Top right: Von Kossa/Toluidine blue stain showing
decreased calcification
(B) µCT analyses of P21 humeri. The deltoid tuberosity (DT) and growth plate (GP) are
indicated with arrows.
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In comparison, we examined development of trabecular bone in cartilage-specific ColIIGSK-3β KO mice (22). Surprisingly, we observed a decrease in the amount of trabecular
bone in the P0 ColII-GSK-3β KO mice, opposite to the phenotype obtained with the
ColI-cre driver line (Fig. 3.10A). µCT was conducted on P21 ColII-GSK-3β KO mice
and significant differences relative to control mice were not observed (Fig. 3.10B).
The P0 ColI-GSK-3β KO mice show increased trabecular bone but that phenotype was
not maintained throughout the post-natal period to P21. The loss of this phenotype could
be due to increased bone resorption, similar to heterozygous global KO mice (21). To
examine osteoclast activity in our mutant mice, we performed TRAP staining. TRAP
staining increased in ColI-, but not in ColII-GSK-3β KO mice (Fig. 3.11). This effect
was most apparent at P0 and less at P21, similar to the lengths of trabeculae. We also saw
a transient increase in serum Rankl levels at P0 that by weaning changed to a decrease,
whereas the serum OPG levels appeared unchanged at both pre- and post- weaning ages
(Fig. 3.12A). Interestingly, Western blotting showed that Rankl protein expression was
increased significantly in the cartilage of P0 mutant mice but not in the calvarial samples
(Fig. 3.12B).

3.3.6

GSK-3β regulates proliferation, cell cycle and apoptosis in skeletal
cells

Having demonstrated that loss of GSK-3β in skeletal cells leads to expanded growth
plates and longer trabeculae, we next investigated the cellular and molecular mechanisms
involved. Expression of proliferating cell nuclear antigen (PCNA), a marker of
proliferation, was examined by IHC of P0 tibiae and by Western blot using extracts of
cartilage and calvariae (Fig. 3.13A). Both IHC and Western blot showed a significant
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Figure 3.11 (27) – Increased osteoclast number in KO mice
(A) Tartrate-resistant Acidic Phosphatase (TRAP) staining for osteoclasts (purple) of
tibia of both ColI-GSK-3β (left) and ColII-GSK-3β (right) KO (KO) and Control (Cont)
P0 mice (top), and P21 mice (bottom).
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Figure 3.12 (28) – RANKL and OPG serum and tissue expression
(A) Serum levels of RANKL were determined by multiplex analysis. Left: Comparison
of mice at P0 by t-test reveals no significant difference between genotypes due to
variability (n=3). Middle: Serum RANKL levels in weaned mice at 2-6 months (n=8).
Right: Serum OPG levels in weaned mice (n=10).
(B) Tissue levels of RANKL in both cartilage (n=5) and calvarial tissue (n=5).
Quantitative data were compared using t-test analysis, significant differences are denoted
by asterisk (*: p < 0.05).
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increase in PNCA expression in both cartilage and bone of ColI-GSK-3β KO mice. IHC
showed that proliferation was increased in the resting and proliferating zones of the
growth plate as well as in cells surrounding the trabecular bone (Fig. 3.13A arrows).
In order for differentiating chondrocytes to progress from proliferating to hypertrophic
cells, they must exit the cell cycle. The cyclin-dependent kinase inhibitor p57 is a key
regulator of cell cycle exit in cartilage (37-39). Western blot analyses demonstrated a
40% increase in p57 in ColI-GSK-3β mutant cartilage that was confirmed by IHC where
p57 was seen increased in the prehypertrophic region of the growth plate (Fig. 3.13B).
This result was also shown in our recent publication using pharmacological inhibitors of
GSK-3β on tibia organ cultures (22). In contrast, there was a significant decrease in
calvarial p57 levels in KO mice (Fig. 3.13B).
During cartilage replacement by bone, hypertrophic chondrocytes undergo apoptosis, the
efficiency of which affects both the size of the hypertrophic zone and bone length.
Apoptosis was examined by TdT-mediated biotin 16-dUTP nick-end labelling (TUNEL)
on P0 tibia sections, as well as by IHC and Western blot analyses of caspase 3 cleavage
(Fig. 3.13C). Western blot analysis demonstrated a decrease in both pro-caspase 3 and
cleaved caspase 3 in mutant cartilage. In contrast, no clear effects of GSK-3β deficiency
on cleaved caspase 3 were detectable in calvaria while pro-caspase appeared reduced
(Fig. 3.13C). IHC of P0 tibia probed with an antibody against caspase 3 showed a similar
decrease in hypertrophic KO cartilage (Fig. 3.13C). TUNEL also demonstrated a
decrease in apoptosis in late hypertrophic chondrocytes in KO mice (Fig. 3.13C).
Therefore, ColI-driven GSK-3β deletion resulted in enhanced growth plate chondrocyte
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Figure 3.13 (29) – Proliferation, cell cycle and apoptosis
(A) Examination of cell proliferation using proliferating cell nuclear antigen (PCNA) as a
marker. Western blot analyses for PCNA (P) (loading control β-actin (A)) from growth
plate cartilage and calvarial extracts of control (C) and knockout (K) mice.
Representative IHC of P0 tibia growth plates as well as trabecular bone probed with
PCNA antibodies, with increased positive staining in KOs marked by arrows.
(B) Western blot analyses with p57 antibodies and densitometry on growth plate cartilage
(n=8). IHC demonstrates that p57 staining is specifically increased in the prehypertrophic
cells of the growth plate.

(Bottom) Densitometry of Western blotting of calvarial

extracts shows a significant decrease in p57 (n=7) in mutant samples.
(C) Apoptosis analyses using cleaved caspase 3 and TUNEL assay. (top) Western blot
analysis showing reduced levels of total and cleaved caspase 3 in mutant cartilage
samples. (bottom left) IHC of paraffin sections of P0 tibia, positive cells are stained
brown (arrow). (bottom Right) P0 tibia probed with a TUNEL assay, positive cells are
stained brown (arrows).
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proliferation and cell cycle exit, decreased apoptosis as well as increased osteoblast
proliferation.

3.3.7

Increased expression of β-catenin in mutant skeletons

To determine the mechanisms underlying the described phenotypes, we examined a
mediator of Wnt signaling known to control endochondral ossification and to be directly
regulated by GSK-3β, namely the transcription factor β-catenin (40-44). Western blot
analyses demonstrated an increase in β-catenin protein in both cartilage and calvariae of
ColI-GSK-3β mutant mice (Fig. 3.14A). IHC of P0 tibia revealed that the number of cells
exhibiting nuclear β-catenin increased in the resting zone close to the articular surface
and in the prehypertrophic zone in KO mice (Fig. 3.14A Resting, Hypertrophic).
Although the background staining is high and similar in both control and KO IHCs of
trabeculae, there are more darkly stained cells surrounding the trabecular bone in KO
sections (Fig. 3.14A Trabeculae). These results suggest that skeleton-specific ablation of
GSK-3β increases canonical Wnt/β-catenin signaling in both cartilage and bone tissue.
Sox9 (45-47) and Runx2 (21,48) are transcription factors that are essential for
chondrocyte and osteoblast differentiation and are regulated directly by GSK-3β or βcatenin. We observed a tissue-specific up-regulation of Sox9 in cartilage as well as a
bone-specific increase of Runx2 protein in our KO mice (Fig. 3.14B). A similar trend in
terms of Runx2 protein levels was seen in cartilage lysates, but the degree of variability
precluded statistical significance.

Thus, GSK-3β regulates the expression of key

transcription factors for cartilage and bone development, possibly through β-catenindependent pathways.
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Figure 3.14 (30) – Expression of key transcription factors
(A) Analyses of β-catenin protein. Left: Western blot analyses with β-catenin (β-cat)
antibody (loading control β-actin (A)) from cartilage (cart) and calvarial (Calv) extracts
of control (C) and knockout (K) mice. Right: Quantitative densitometry; data were
normalized to control sample for cartilage (n=8) and calvaria (n=7). Representative IHC
of P0 tibia sections probed with β-catenin antibodies. Arrows indicate nuclear β-catenin.
(B) Western blot analyses with Runx2 and Sox9 antibodies (loading control β-actin (A))
from cartilage (Cart) and calvarial (Calv) extracts of control (Cont) and knockout (K)
mice. Blots were then analyzed by quantitative densitometry (n=8).
Quantitative data were compared using t-test analysis, significant differences are denoted
by asterisk (*: p < 0.05).
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3.4 Discussion
This study has examined the effects of Col I cre-driven inactivation of the Gsk3b gene.
The resultant effects included delayed development of specific skeletal structures as well
as altered osteoblast and osteoclast physiology. The primary cause of these phenotypes
appears to be loss of GSK-3β in osteoblasts and potentially perichondral cells. While we
saw a reduction in GSK-3β protein in growth plate chondrocytes, our previous study of
cartilage-specific ablation of GSK-3β (22) showed none of the phenotypes described
here, which is further supported by side-by-side comparisons between ColII-GSK-3β
(22) and ColI-GSK-3β KO mice in the current study. For example, cartilage-specific loss
of GSK-3β causes the opposite trabecular phenotype as Col1-driven inactivation. Thus,
it is unlikely that partial loss of GSK-3β in chondrocytes contributes to the described
bone phenotypes. Moreover, we did not observe a reduction in GSK-3β levels in a variety
of other tissues, indicating the specificity of gene recombination in our mice.
On the other hand, the numerous cartilage growth plate phenotypes obtained using the
ColI cre driver line is startling, especially in light of the absence of phenotypes obtained
in cartilage-specific Gsk3b KO mice in our earlier study(22). Loss of GSK-3β was less
pronounced and, according to our immunohistochemistry data, appeared later in
chondrocyte differentiation in this study compared to data from our ColII-GSK-3β mice.
Thus, it is unlikely that the cartilage phenotypes observed here are due to loss of GSK-3β
in chondrocytes alone and several alternative explanations seem feasible. First, it is quite
possible that altered signaling from the perichondrium and/or osteoblasts (both of which
show Cre expression) affects chondrocyte physiology. For example, it is plausible that
loss of apoptosis-inducing factors from osteoblasts results in reduced apoptosis of
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hypertrophic chondrocytes and thus the elongation of the hypertrophic zone. A second
possibility is that systemic alterations in metabolism and endocrine signaling in our Col1GSK-3β KO mice (described in the accompanying manuscript) affect growth plate
chondrocytes directly or indirectly.
Our mutants displayed examples of both advanced and delayed ossification. Interestingly,
advanced ossification was also observed in heterozygote global GSK-3β KO mice (21)
while delayed skeletal development was seen in homozygote global GSK-3β KO mice at
birth (20). Furthermore, it has been shown in vitro through both genetic manipulation
and use of pharmacological inhibitors that disruption of GSK-3β activity increases bone
formation by cultured osteoblasts (21). Advanced ossification, as shown for example by
longer trabeculae, is likely due to direct changes in osteoblasts, such as increased cell
proliferation and elevated expression of Runx2 and β-catenin in the absence of GSK-3β.
In contrast, the examples of delayed ossification could be due to secondary effects, such
as increased osteoclast activity or metabolic changes (accompanying manuscript).
Furthermore our observations within the growth plate, specifically the delay in
hypertrophic apoptosis and cartilage to bone turnover, not only explains the decrease in
longitudinal bone growth but some of the skeletal developmental delays. This delay in
the conversion of cartilage to bone likely explains the pelvic phenotype and possibly also
that of the deltoid tuberosity, which forms through endochondral ossification (32).
However, one alternative explanation for the later is that altered signals from the tendon
such as BMP4 (32) contribute to the mutant phenotype.
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Our ColI-GSK-3β KO mice showed increased proliferation of growth plate chondrocytes
as well as increased expression of the cell cycle inhibitor p57, indicating that these
rapidly proliferating cells were also becoming hypertrophic at a greater rate. In
conjunction with the observed decrease in apoptosis, this data can account for the longer
hypertrophic zone seen in P0 KO mice. We also observed increases in osteoblast
proliferation, collagen production, calcification and trabecular bone formation, indicating
that the tissue-specific reduction in GSK-3β promotes endochondral bone formation.
However, these data (increased chondrocyte proliferation and hypertrophy, increased
bone formation) seem to contradict the observed reduction in long bone length observed
in these mice, and indeed GSK-3 inhibition in tibia organ culture enhances longitudinal
bone growth (22). It has also been shown that heterozygous deletion of GSK-3β partially
rescues growth retardation caused by deletion of cGMP-dependent protein kinase II
(cGKII) (49). Therefore, one would expect that homozygous deletion in skeletal tissue
would cause increased bone growth, contrary to what we actually observed. However,
while bones are slightly shorter in our KO mice, the effects on whole body weight are
more pronounced and precede changes in bone length. Based on our accompanying
manuscript, we believe that deletion of GSK-3β in bone results in systemic suppression
of body growth through metabolic effects, but the direct roles of GSK-3β in skeletal cells
partially compensates for these effects, explaining why bone growth is less affected than
overall body size.
While some of the effects observed here are likely due to increased β-catenin levels and
thus activation of the canonical Wnt pathway, it is unlikely that this pathway is solely
responsible for the phenotypes described here. For example, inactivation of GSK-3β
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mediates some of the effects of the PI3K-Akt pathway that acts downstream of many
growth factors (10,15,50). Akt1 directly inactivates GSK-3β, and Akt1 KO mice display
a phenotype opposite to that described here, especially with regard to chondrocyte
hypertrophy and osteoclast activity (28,51). These data suggest that increased GSK-3β
activity is responsible for some of the phenotypes observed in Akt1 KO mice.
Furthermore, GSK-3β is a major node connecting other signaling pathways, including
hedgehog/Gli (52), BMP/Smad (53), and NFAT (54). GSK-3 is also a central factor
connecting transcription to protein synthesis, through its regulation of translation (e.g.
TSC2 (55), eIF2B (56), S6K(57))

and energy metabolism (e.g. insulin signaling,

glycogen synthesis (58)). Clearly, some of these processes could be affected in our KO
mice and contribute to the complex phenotypes observed.
While many function of GSK-3 proteins appear to be ubiquitous, there are several
examples of tissue specific roles (16,17,59). We observed several tissue-specific effects,
including chondrocyte-specific up-regulation of p57, Sox9, caspase 3 and GSK-3α, and
up-regulation of Runx2 by osteoblasts. Runx2 is a known target of GSK-3β (21) and βcatenin (60) in osteoblasts, and therefore its upregulation in KO bone is not surprising.
Sox9 is thought to act antagonistically to β-catenin in cartilage (45,61) and is not
expressed in hypertrophic chondrocytes, where we observed up-regulation of β-catenin.
The observed upregulation of Sox9 is therefore likely a secondary effect, potentially due
to altered signaling from the perichondrium (52,62).
The deletion of both Gsk3b alleles specifically in skeletal cells in this study provides a
novel model to study the role of GSK-3β in postnatal skeletal development. Our data
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suggest that GSK-3β not only affects osteoblast biology directly, but also controls
skeletal development indirectly through signaling to the growth pate. While the
phenotype of these mutant mice is very complex and requires further characterization,
our data already provide novel insights into GSK-3 function in the skeleton and possibly
whole body metabolism.
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Chapter 4

4

Skeleton-specific deletion of GSK-3β causes insulin
sensitivity and male specific mortality due to possible
development of type II diabetes

A version of this article was submitted for publication as an original research article:
Gillespie JR, Bush JR, Bell GI, Aubrey LA, Ferron M, Kream B, DiMattia G, Patel S,
Woodgett JR, Karsenty G, Hess DA, Beier F. Skeleton-specific deletion of GSK-3β
causes insulin sensitivity and male specific mortality due to possible development of type
II diabetes. Submitted to JBMR, December 2011.
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4.1 Introduction
Glycogen synthase kinase 3 beta (GSK-3β) has been known for over thirty years to be
regulated by insulin signaling where it functions to regulate the activity of glycogen
synthase (1). More recently, the two mammalian forms of GSK-3 (α and β) have been
shown to be downstream of a signaling cascade from the insulin receptor through PI3K
and the protein kinase AKT (PKB), which results in GSK-3 α and β inhibition through
phosphorylation of Serines 21 and 9, respectively (2,3).

However, the role of GSK-3 is

much more complex as it also negatively regulates many other signaling pathways such
as Wnt (4,5), NFAT (6), PTH (7), and BMP (8). A recent review attempted to classify
the many substrates (>100) of GSK-3β into functional activities such as endocrine,
growth and development, neurobiology, and immunology (9).
The physiological functions of the two forms of GSK-3 has been highly debated in the
literature, sometimes with evidence of overlapping roles and other times distinct roles,
often in a tissue-specific manner (10-15). In fact, our own work has shown differential
expression patterns within the growth plate of long bones as well as specific upregulation
of GSK-3α in GSK-3β-depleted chondrocytes in vivo (12). In contrast, we also show in
the accompanying manuscript (accompanying manuscript) that GSK-3α is expressed at
low levels in osteoblasts and is not induced in response to the loss of GSK-3β in
bone/calvarial tissue. Moreover, our skeleton-specific deletion of the Gsk3b gene through
the use of the rat Col1a1 promoter to drive Cre recombinase expression (ColI-GSK-3β
KO mice), resulted in significantly reduced body weight that preceded a decrease in
longitudinal bone growth (Gillespie et al., accompanying manuscript). This suggests that
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loss of GSK-3β in bone affects whole body metabolism, a model that is consistent with
recent studies demonstrating the role of bone as a regulator of body metabolism (16-18).
Recent publications studying osteoblast-specific insulin receptor knock-out (KO) mice
(ObIR-KOs) have demonstrated that osteoblast insulin signaling modulates body
metabolism (16,17).

These reports determined that insulin signaling influences

circulating levels of the hormonal, under-carboxylated form of osteocalcin from
osteoblasts through regulation of FoxO1 activity (16) and the Twist2/Runx2 pathway
(17). Bone-derived under-carboxylated osteocalcin, in turn, regulates pancreatic beta cell
mass and area as well as glucose tolerance and insulin sensitivity. In conjunction with the
known role of GSK-3 as an inhibitor of insulin signaling, these data suggest that
skeleton-specific inactivation of the Gsk3b gene should cause a metabolic phenotype
opposite to that seen for bone-specific inactivation of the insulin receptor (16,17). This
prediction was tested in the current study.

4.2 Material and methods
4.2.1

Materials

The following antibodies were utilized in this study: actin A5441, S6 #2317, pS6 #4856,
insulin #I2018 (Sigma Chemical Co., St. Louis, MO); goat anti-rabbit hrp sc-2004 (Santa
Cruz Biotechnology, Santa Cruz, CA); GSK-3β #9315, pGSK-3β #9336, GSK-3α #9338,
(Cell Signaling Technology, Davers, MA). General chemicals and supplies were
purchased from Sigma and VWR (Radnor, PA).
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4.2.2

Mouse breeding and genotyping

Mice homozygous for floxed Gsk3b alleles (Gsk3bfl/fl) have been described previously
(12,14,19,20)(Gillespie et al, accompanying manuscript) and were crossed with mice
expressing cre recombinase under the control of an osteoblast-specific 3.6kb fragment of
the rat Col1a1 promoter (21,22) (accompanying manuscript). Male mice heterozygous
for the floxed Gsk3b allele and expressing Col1a1 cre were backcrossed with
homozygous Gsk3b floxed female mice. The offspring from these crosses were analyzed.
Mice were housed under a 12 hr light-dark cycle and fed tap water and regular chow ad
libitum. All procedures involving animals were approved by the University of Western
Ontario Animal Care and Use Committee. PCR genotyping was performed from ear
notch DNA using primers 5’-GGGGCAACCTTAATTTCATT-3’ (forward) and 5’TCTGGGCTATAGCTATCTAGTAACG-3’ (reverse) for GSK-3β for 30 cycles of 96 οC
55sec, 56.5οC 45 sec, 68 οC 2:45min to amplify products. The cre transgene was detected
using

the

primers

5’-CACACTGTGTAGTGCTTCGT-3’

(forward)

and

5’-

CCTCCAAACCATCCAAGAT-3’ (reverse) using 40 cycles of 95 οC 45sec, 58 οC 30sec,
72 οC 1min.

4.2.3

Histology and immunohistochemistry (IHC)

Freshly dissected mouse tissues (kidney, urogenital tract, pancreas) were fixed in 4%
paraformaldehyde overnight before embedding and sectioning at the Robarts Research
Institute Molecular Pathology Core Facility (London, ON). 5µm sections were dewaxed
in xylene followed by a graded series of alcohol washes, 100% x2, 95% x1, 70% x1.
Sections were stained with H&E staining. IHC sections were incubated in 3% H2O2 for
15 min at room temperature, followed by incubation in 10 mM sodium citrate at 95 οC for
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30-60 min for antigen retrieval and blocking with 5% goat serum in PBS (23-26).
Sections were incubated with primary antibody overnight at 4 οC, washed 3 times in PBS,
and secondary antibody was applied according to manufacturers’ recommendations. For
detection, DAB substrate was used and counterstained with methyl blue. All images
were captured with a Leica DME microscope fitted with a Qimaging Micropublisher 5.0
RTV camera using QCapture Pro 5.1 software.

4.2.4

Western blot analyses

Fresh calvariae and cartilage from long bones were dissected from P0 mice in cold
Puck’s solution A (PSA) (12,24,27). Organs (kidney and urogenital tract) were dissected
and placed directly in RIPA buffer flash frozen and stored at -20 οC overnight, then
homogenized, sonicated and centrifuged. Total protein content was determined, and 2535µg total protein was loaded per lane into precast NuPAGE Novex Midi Tris-Acetate
Gels and separated using the XCell Surelock Mini-cell (Invitrogen) system. Gels were
blotted using XCell II Blot Module (Invitrogen) as per manufacturer’s instructions. Blots
were blocked in 5% BSA TBST solution for 1 hour, and then probed with primary
antibody overnight at 4 οC followed by appropriate secondary antibody (HRP-conjugated)
for one hour at room temperature, and the resultant signal was detected using the ECL
detection system (Amersham). Representative blots from at least 3 independent pairs of
littermates are shown.

Quantitative densitometry analysis was conducted using a

ChemiImager 5500 system, subtracting background and normalizing to β-actin loading
control signal.

Densitometry results were converted relative to control, allowing

comparison between blots by t-test analysis.
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4.2.5

Blood glucose and serum measurements (Millipore Multiplex),
glucose tolerance test and insulin tolerance test

Mouse blood glucose measurements were conducted using a Contour glucose meter. The
non-fasted or random-fed readings were measured between 9-10 a.m. The fasted readings
were taken from mice that had the food source removed for 6hrs. For the glucose
tolerance test (GTT), both control and ColI-GSK-3β KO mice were injected IP with
2.5g/kg body weight of glucose after a 5-6hr fast, and measurements were taken from tail
vein blood. For the insulin tolerance test (ITT), control and ColI- and ColII-GSK-3β
mice were injected IP with 0.2 U/kg body weight of insulin, and glucose readings were
taken from a tail vein. Serum readings were performed using a Millipore Multiplex
system on the mouse bone panel 2A (Cat No. MBN2A-41K), Adiponectin-Single plex
(Cat No.MADPK-71K-ADPN) and Osteocalcin Single Plex (Cat No. MBN-41K-1OC) in
the Screening Lab for Immune Disorders, St Joseph Hospital, London, Ontario, Canada.
Serum carboxylation state of osteocalcin was measured as described (16).

4.2.6

Statistical analysis

All data were collected from at least 3 independent pairs of littermates. Data was
expressed as mean ±SEM, and p values under 0.05 were considered significant.
Statistical significance was determined by t-test or 2-way ANOVA analysis comparing
control to KO littermates using GraphPad Prism 3.00 for Windows. Western blot
densitometry data were normalized to controls in order to compare between blots by ttest.
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4.3 Results
4.3.1

Metabolic changes and male specific mortality in skeleton-specific
GSK-3β KO mice

In our accompanying study we examined the skeletal effects of using a 3.6 kb fragment
of the rat collagen I promoter to specifically delete GSK-3β from bone-forming
osteoblasts (Gillespie et al., accompanying manuscript). These mice were dwarfed with
shorter bones than control mice, which was in contrast to our ex vivo studies where we
recorded an increase in bone growth upon pharmacological inhibition of GSK-3(12). The
dwarfed phenotype was also surprising since GSK-3 serves as a “brake” on many
anabolic pathways such as Wnt and Insulin/IGF (1,2,4,28-30). Interestingly, the delay in
skeletal growth occurred postnatally and was preceded by a reduction in weight. Here we
show that the reduction in length of skeletal elements was not proportional to the
reduction in weight (Fig. 4.1A). Each skeletal element is longer in mutant mice when
described relative to the animal’s weight. This result indicates that the reduction in
weight is largely not due to loss of skeletal weight and likely due to loss of another tissue,
such as fat or muscle. One of the KO animals with the most severe weight reduction is
shown with its littermate (Fig. 4.1A). The mutant mouse is almost 60% lighter than the
littermate control, while the size of its limbs and skull are affected to a far lesser degree
(Fig. 4.1A).
In addition, nearly all of the male ColI-GSK-3β KO mice died between weaning and 7
months of age (Fig. 4.1B) whereas only 1 female ColI-GSK-3β and none of the ColIIGSK-3β KO mice died within this interval (12). This male-specific mortality resembles a
recent study of low birth weight animals where male mice expire due to development of
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Figure 4.1 (31) Metabolic phenotype (Glucose) in ColI-GSK-3β KO mice
(A) (right) Longitudinal measurement of skeletal elements in proportion to the animal’s
weight for ColI-GSK-3β KO (KO) mice compared with control littermates (Cont) (n=4).
(left) An example of a severely underweight mutant mouse (60%) with limb and skull
sizes not proportional to its low weight.
(B) Survival curves (Kaplan-Meier Plot) of both male and female of ColI- and ColIIGSK-3β KO mice tracked for 1 year.
(C) Blood glucose levels (mmol/L) of both ColI- and ColII-GSK-3β KO (KO) at birth
(P0). The table also lists glucose readings from weaned mice (2-6 months) in both the
fasted (6 hrs) and random fed (Fed) state for both male and female ColI-GSK-3β mice.
The last row shows the data for male mice that had a glucose reading performed close to
their death (1-2 weeks prior to death).
Quantitative data were compared using t-test analysis, significant differences are denoted
by asterisk (*: p < 0.05, **: p<0.01).

141

diabetes (31,32). In light of this similarity and recent findings describing osteoblasts as
endocrine regulators of glucose metabolism (16-18,33,34), we examined blood glucose
levels (Fig. 4.1C). Interestingly, the blood glucose levels of the bone-specific KO mice
were significantly reduced at birth compared to control littermates, which is in contrast to
chondrocyte-specific KO mice (12) that showed no changes in blood glucose levels (Fig.
4.1C). Pronounced hypoglycemia is apparent in skeleton-specific KO pups when glucose
readings were taken prior to first feeding (data not shown) and could explain the 30%
mortality at birth (Gillespie et al, accompanying manuscript). Weaned female mice,
ranging from 2-6 months of age, showed a significant decrease in blood glucose after
fasting for 6hrs, whereas the male mice did not show a significant difference. The nonfasted or random fed glucose levels were also examined in weaned mice, and both female
and male mice showed a reduction in glucose blood levels. The reduction in non-fasted
glucose levels appears greater and more consistent in male mice (individual littermate
pairs shown in Fig. 4.2A,B). Several of the male mice, which showed reduced non-fasted
glucose levels, became hyperglycemic prior to their premature death (Fig. 4.1C), with a
maximum reading of 16.9 mmol/l. Furthermore, glucose was detectable in the urine of
most of the male KOs prior to death (data not shown).

4.3.2

Serum insulin and leptin levels in skeleton-specific GSK-3β KO
mice

To examine potential causes of reduced blood glucose, we examined the levels of several
endocrine regulators of metabolism. Serum insulin is significantly decreased at birth and
post-weaning in skeleton-specific GSK-3β KO mice (Fig. 4.3A). Both genders displayed
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Figure 4.2 (32) Individual glucose readings
(A) Individual glucose readings for male mice in the non-fasted or random fed state
relative to control.
(B) Individual glucose readings for female mice in the non-fasted or random fed state
relative to control.
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Figure 4.3 (33) Serum insulin and leptin are decreased in KO mice
(A) Comparison of serum insulin levels (Millipore Multiplex) between control (Cont) and
knockout (KO) mice at P0 (n=3) (Left) and in weaned mice (n=8) (Right).
(B) Analyses of phosphorylation level of S6 in ColI-GSK-3β KO mice. Western blot
analyses from tissue samples of cartilage (n=5) and calvarial (n=6) protein extracts from
control (Cont) and knockout (KO) mice (normalized to total S6).
(C) Determination of GSK-3β expression in various tissues using densitometry of
Western blots: fat, liver, kidney, muscle, and pancreas (n = 4).
(D) Examination of serum leptin levels (Millipore Multiplex) in ColI-GSK-3β KO and
control mice at P10 (n=5) and in weaned mice (n=8).
(E) Analyses of serum adiponectin levels (Millipore Multiplex) in ColI-GSK-3β KO and
control mice at P10 (n=5) and in weaned mice (n=10).
(F) Histology of gonadal adipocytes shows reduced cell size.
Quantitative data were compared using t-test analysis, significant differences are denoted
by asterisk (*: p < 0.05).
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Figure 4.4 (34) Individual insulin readings
Individual Insulin reading relative to control.
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reduced insulin levels post weaning (individual littermate pairs results displayed Fig.
4.4A); interestingly, the one male KO that did not show this trend was the only one to
survive to one year of age. We analyzed the phosphorylation of ribosomal protein S6
protein, a downstream target of the insulin/mTOR/S6K pathway (3,35,36). Cartilage and
calvarial extracts from skeleton-specific GSK-3β KO mice displayed reduced levels of
phosphorylated S6, in agreement with reduced insulin levels and subsequent reduction in
mTOR signaling (Fig. 4.3B).
GSK-3β protein levels were examined in metabolically active tissue to confirm that the
observed phenotypes were not partially caused by aberrant cre expression and subsequent
non-specific GSK-3β deletion (Fig. 4.3C). Although GSK-3β levels actually appeared to
trend toward increased levels in several tissues of the KO mice, statistical analyses did
not support significant differences in GSK-3β protein levels between control and KO
pancreas, liver, fat, muscle or kidney (Fig 4.3C). The GSK-3β levels in the muscle (data
not shown) and pancreas (Fig. 4.5) were also measured by ELISA, and no significant
differences between control and mutant mice were found.
Examination of other metabolic hormones revealed that the skeleton-specific GSK-3β
KO mice displayed significantly reduced serum leptin levels at P10 and after weaning
(Fig. 4.3D). The ColI-GSK-3β KO mice also had lower adiponectin serum levels at P10
but not in weaned mice (Fig. 4.3E). Lower leptin and adiponectin levels are indicators of
a metabolic phenotype and possibly reduced body fat content. We examined adipocyte
histology, and the mutant mice possessed much smaller adipocytes (a representative
image from gonadal fat is displayed in Fig. 4.3F). Given the reduction in leptin,
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Figure 4.5 (35) GSK-3β ELISA
GSK-3β ELISA data on female pancreas.
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Figure 4.6 (36) Food intake
Food intake, (right) food (g) intake per animal per day, (left) food intake relative to
animal weight
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adiponectin and adipocyte size we investigated whether the mutant mice consumed
different amounts of food (Fig. 4.6). Although there was a trend toward less food
consumption per day in mutant mice, this was not statistically significant (Fig. 4.6 left).
Furthermore, when food consumption was standardized to animal weight, the mutant
mice ingested the same amount of food as control mice (Fig. 4.6 right).
We then examined osteocalcin (OCN) since its under-carboxylated form has been
identified as an osteoblast-derived hormone that is regulated by the insulin pathway (1618). However, in weaned, 2-6 month-old, mice we could not detect changes in total or
carboxylated osteocalcin (data not shown).

4.3.3

ColI-GSK-3β KO mice display increased insulin sensitivity

ColI-GSK-3β KO mice displayed a phenotype in terms of blood glucose, Runx2 and
bone formation (Gillespie et al., accompanying manuscript) that contrasted the bonespecific insulin receptor KO mice (16,17). However, insulin levels were decreased in
both models (16,17). Since the presence of both low glucose and low insulin levels in
our mice was perplexing, we next examined insulin tolerance/sensitivity.

These

experiments were conducted in female mice because male mice were dying and changing
metabolically from low to high blood glucose at apparently random ages post weaning.
However, prior to this change in glucose concentration, the metabolic profile of both
genders appeared similar (Fig. 4.1). Insulin tolerance tests (ITT) on female ColI-GSK-3β
KO mice revealed that they were significantly more insulin sensitive than their control
littermates (Fig. 4.7A). The area under the curve was significantly lower in mutant mice
(e.g., mutant mice showed an overall stronger reduction in blood sugar levels in response
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to insulin injection; Fig. 4.7A). In contrast, female cartilage-specific GSK-3β KO mice
showed similar insulin responses to their control littermates (data not shown).
Moreover, a glucose tolerance test (GTT) showed no difference between KO and control
mice (Fig. 4.7A). Finally, histological analysis of the pancreas showed similar insulin
immunostaining and islet size between control and ColI-GSK-3β mice (Fig. 4.7B, Fig.
4.8A & B). Both islet number and circumference showed no significant changes in
mutant mice (Fig. 4.8A & B). IHC demonstrated no differences in GSK-3β expression in
control or mutant mice (Fig. 4.8C), further validating the specificity of our Cre line.
Given the Western blot (Fig. 4.3C), IHC (Fig. 4.8C), and ELISA (Fig. 4.5) results for
GSK-3β protein levels in our mutant mice, we are confident that GSK-3β was not ablated
in pancreatic tissue.

4.3.4

Large bladder at time of death in male ColI-GSK-3β KO mice

We next sought to understand the basis for the consistent premature death of male KO
mice. Prior to their death (3-6 hours), we noticed that these mice presented with a
hunched posture and a hard mass in their abdomen (Fig. 4.9). The mass was revealed to
be a large, distended and full bladder (Fig. 4.9A). The volume of the bladder was almost
5 times that of control littermates and the urine had a reddish colour, suggesting blood
was present (Fig. 4.9A). Histology demonstrated that the bladder structure in terms of
muscle layers and shape was completely disrupted in the KO male mice that died
prematurely (Fig. 4.9B). However, bladders of male mice not obviously unhealthy or
disabled, as well as of female mice, were not significantly different from controls
(Fig.4.9B). To ensure that aberrant loss of GSK-3β in the bladder was not responsible for

151

152

Figure 4.7 (37) ColI-GSK-3β KO mice show increased insulin sensitivity
(A) (Top) Insulin tolerance test (ITT) for female ColI-GSK-3β KO (KO) compared to
control littermates. (Bottom Left) Area under the curve (AUC) analysis for the ITT of
the ColI-GSK-3β KO and control mice. (Bottom Right) Glucose tolerance test results for
ColI-GSK-3β mice.
(B) Examination of insulin immunohistochemistry and islet size in ColI-GSK-3β mice,
Control (Cont) versus KO.
Quantitative data were compared using 2-way Anova or t-test analysis, significant
differences are denoted by asterisk (*: p < 0.05).

153

Figure 4.8 (38) Pancreas is unchanged in mutant mice
(A) Pancreatic islet number for female mice.
(B) Pancreatic islet circumference for female mice.
(C) Immunohistochemistry using GSK-3β antibodies of female pancreas.
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Figure 4.9 (39) Enlarged bladders in male mutant mice that expire prematurely
(A) Comparison of bladder size from male ColI-GSK-3β KO (KO) mice that died
relative to age-matched control (cont) littermates. (Top Middle) Urine extracted from
bladders of KO mice by syringe. (Right) Comparison of bladder volume (n=4).
(B) Histological analysis of the bladder from a male KO mouse that died with an
extended bladder (top right panel) relative to age-matched control bladder on the left.
The panels below show bladder morphology in male and female mice at 3 months of
ages.
(C) Immunohistochemical staining of GSK-3β of male bladders from control and KO
mice.
Quantitative data were compared using t-test analysis, significant differences are denoted
by asterisk (*: p < 0.05).
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this phenotype, IHC was performed on tissue sections (Fig. 4.9C).

The cells of the

epithelial layer uniformly stained for cytoplasmic GSK-3β in both control and KO mice,
whereas the lamina propria was stained more sporadically with increased nuclear
reactivity (Fig. 4.9B).

4.3.5

Damage to the corpus cavernosum in male ColI-GSK-3β KO mice

Since the large bladder could be explained by an obstruction in the urinary tract, we
dissected and histologically examined the male urogenital tract from the external penis to
the pelvic ureter. Male KO mice that died prematurely displayed a large swollen corpus
cavernosum (Fig. 4.10). The highest magnification revealed the corpus cavernosum to be
filled with red blood cells. The corpus cavernosum is associated with erectile dysfunction
and has been studied in obesity and type II diabetes in various mouse models (37-39).
Our observations indicated that the higher serum glucose readings in the KO mice
predicted a significantly damaged corpus cavernosum with blood present (Fig. 4.11).
Interestingly, this phenotype was present in KO mice that were sacrificed even before
displaying an extremely distended bladder. GSK-3β IHC showed that both the control
and KO bladders have similar levels of staining in the layer of cells surrounding the
cavity of the corpus cavernosum (Fig. 4.12A).
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Figure 4.10 (40) Male mutant mice display damage to the Corpus Cavernosum
(A) Examination of male urogenital tract of a male ColI-GSK-3β KO (KO) mouse that
expired prematurely compared to control littermate (Cont). (Top) Whole-mount display
of the urogenital tract showing external penis (Ex), seminiferous vesicles (SV), testis (T),
and swollen and dark coloured corpus cavernosum (CC)(circled). (Middle) Histological
sections through the urogenital tract showing a blood filled corpus cavernosum in mutant
mice (circled), with high magnification images below showing the presence of red blood
cells (Bottom).
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Figure 4.11 (41) Examples of damage
(Top) Corpus cavernosum of the urogenital tract of male ColI-GSK-3β KO mice that had
slightly elevated (Left) and high blood glucose (Right) when compared to their control
littermates. (Middle) Higher magnification of the above corpus cavernosum to examine
blood cells present. (Bottom) Kidney of male ColI-GSK-3β KO mice that had slightly
elevated (Left) and high blood glucose (Right) when compared to their control
littermates.
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Figure 4.12 (42) GSK-3β Immunohistochemistry of kidney and urogenital tract.
(A) Corpus cavernosum stained (brown) by immunohistochemistry using GSK-3β
antibodies.
(B) Immunohistochemistry staining (brown) of GSK-3β protein in renal cortex and
higher magnification of tubules and glomeruli.
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4.3.6

Kidney damage and hydronephrosis in male ColI-GSK-3β KO
mice

The pathological changes in the corpus cavernosum prompted us to investigate whether
there was damage further upstream in the urogenital tract that could be responsible for
this phenotype. The kidney of mutant male mice was clearly abnormal (Figures 4.13 and
4.14). The calyces (funnel like structures where the collecting ducts pool and leave the
kidney) of ColI-GSK-3β KO were distended, a hallmark of hydronephrosis (Fig. 4.13).
The collecting duct renal pyramids also showed signs of dilation and have lost some of
their characteristic “pyramidal” histology (Fig. 4.13). Abnormalities can also be seen in
the renal cortex where holes/spaces were seen in the mutant (Fig. 4.14). The tubule lining
cells appeared damaged and the luminal space enlarged and full of proteinacious material
(Fig. 4.14). Also, the glomerular space was also not as well defined in KO animals (Fig.
4.14).

This phenotype, similar to the previously described damage to the corpus

cavernosum, appears more pronounced in animals with abnormally high glucose levels
(Fig. 4.11). The kidney damage was also present in animals that had yet to display
enlarged bladders, indicating that hydronephosis preceded the bladder phenotype.
Furthermore, we examined GSK-3β levels in the kidney to ensure that it was not deleted
by aberrant cre expression and found similar IHC staining in the glomerulus and renal
tubules of mutant and control mice (Fig. 4.12B), in agreement with our Western blot
analyses (Fig. 4.3C).
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Figure 4.13 (43) Evidence of kidney damage and hydronephosis in male mutants
(A) Histological sectioning through the kidney of a male ColI-GSK-3β KO (KO) that
expired with a severely distended bladder compared to control littermate (Cont). Figure
shows various magnifications to display structures of the whole kidney, calyces,
collecting ducts, and renal pyramids. Arrows are pointing to the presence of abnormally
large spaces in the kidney of the KO male.
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Figure 4.14 (44) Renal tubule damage
(A) Histological examination of the renal cortex of from a male ColI-GSK-3β (KO) that
died compared to control littermate (Cont). (Middle) Red arrows point to clear spaces
indicating lack of tissue integrity and damage in the KO renal cortex near glomeruli.
(Bottom) Damage to the renal tubules that are full of proteinaccous material (red arrow).
Also the Bowman’s space (BS) is not as defined for the KO glomerulus compared to that
in the control mouse glomerulus (black arrow).
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4.4 Discussion
Our ColI-driven GSK-3β deletion results in a phenotype that is, in many aspects,
opposite to those observed with bone-specific deletion of the insulin receptor gene
(ObIR-KO mice) (16,17). This is in agreement with the role of GSK-3 as a negative
regulator of IR-induced cellular responses (reviewed in (40)). ObIR-KO mice are larger
and weigh more due to increased fat deposits (17), whereas ColI-GSK-3β KO mice weigh
less, possess smaller adipocytes and decreased serum leptin levels. ObIR-KO mice also
displayed decreased trabecular bone formation (17), while our mice show increased
trabecular bone at P0 and P21 (Gillespie et al. accompanying manuscript). The GSK-3β
KO mice described herein exhibited reduced blood glucose levels whereas it was
increased in ObIR-KO mice (17). We also demonstrated an increase in bone Runx2
expression (Gillespie et al., accompanying manuscript), which was reduced in the ObIRKOs (17). Our studies indicated an increase in osteoclast numbers (Gillespie et al.,
accompanying manuscript) whereas IR KO mice displayed decreased bone resorption
(16). Lastly, our ColI-GSK-3β KO were initially more insulin sensitive relative to control
mice, whereas the ObIR-KO mice are insulin resistant (16,17).
However, one important disconnect is apparent between these mouse models (bonespecific GSK-3β and IR ablation); namely, the reduced serum insulin level seen in both
strains. There are several possible explanations for this similarity between the models. At
the molecular level, GSK-3 is not the only downstream mediator of IR-PI3K-Akt
signaling; thus, loss of GSK-3β is unlikely to completely oppose the effects of loss of the
IR. Similarly, GSK-3β is involved in many other signaling pathways, in addition to
insulin, again providing a potential explanation why insulin levels do not follow the same
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patterns as other parameters in the two mouse lines. However, the most likely explanation
is that the observed increase in insulin sensitivity caused a secondary reduction in insulin
levels in our GSK-3β KO mice. Increased insulin sensitivity would cause lower blood
glucose, which could subsequently result in reduced insulin levels in our GSK-3β KO
mice.
Another important difference between our mice and those with osteoblast-specific
inactivation of the insulin receptor is that we did not observe changes in circulating total
or undercarboxylated osteocalcin. In agreement with these data, no changes in the
endocrine pancreas or in glucose tolerance were seen in our skeletal GSK-3β KO mice.
The reductions in leptin and adiponectin in our mutant mice are possibly secondary to the
primary metabolic phenotype, namely the reduction in blood glucose and decreased size
of adipocytes. Consequently, the metabolic differences in our mutant mice are possibly
due to a novel molecular connection between bone and body metabolism that acts in
parallel to osteocalcin-mediated effects. In particular, that pathway might regulate insulin
sensitivity in classical insulin response tissues. By depleting GSK-3β, we activated a part
of the insulin signaling cascade in osteoblasts, indicating to the osteoblast that the body
had excess energy (glucose). Through a still unknown mechanism these osteoblasts then
cause increased insulin sensitivity throughout the body.
Furthermore, the phenotype of adipocytes in the mutant mice suggests that they do not
obtain sufficient glucose to maintain fat storage levels.

Reducing GSK-3 activity has

been shown to increase glucose uptake (41), indicating that increased glucose uptake by
mutant osteoblasts could deprive other tissues of this energy source. Such a scenario is in
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agreement with our observation that the reduction in bone growth in mutant mice occurs
at a later time point during development and is less pronounced than body weight
reduction.
The premature death of male KO mice is one of the most intriguing aspects of our study.
Recently, low birth weight (as observed in our mutant mice (Gillespie et al.,
accompanying manuscript)) has been shown to contribute to male mouse-specific
development of type II diabetes, leading to premature death (31,32).

Indeed, our male

mice show signs of type II diabetes including a trend toward increased blood glucose as
they age, the presence of glucose in their urine, large bladder size and hydronephosis
(42,43). The large bladder phenotype is restricted to dying mutant mice whereas kidney
and urogenital damage were present in KO mice that were sacrificed prior to phenotypic
death. This suggests that the mice are dying of complications due of kidney failure and
that the bladder phenotype is the end stage. Hydronephosis and nephropathy is observed
in mouse (44) and rat (45) models of type II diabetes as well as in human type II diabetes
patients (46). Moreover, kidney failure is a major cause of death from type II diabetes in
humans (47). Interestingly, we recently discovered that one female ColI-GSK-3β KO
died at 1.5 years of age. This mouse displayed the large bladder seen in the males which,
suggest that this phenotype is not strictly a male phenotype, but that the males are much
more susceptible. Higher susceptibility to development of diabetes in males has been
shown in mouse models previously (31,48), and faster progression of renal disease is
associated with diabetes in human males (49).
Finally, a recent study described a mutation in patients that lead to both hypoglycemia
and lack of plasma insulin (50).

These patients were found to have an activating
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mutation in the AKT2 gene (50). Since AKT is a direct inhibitor of GSK-3 activity, the
mechanisms involved in the human disease and our mutant mice might be related. The
fact that we see these phenotypes upon skeleton-specific ablation of GSK-3β further
highlights the role of bone as a central regulator of body metabolism.
In conclusion, our study demonstrates a key role for of bone GSK-3β in the control of
whole body metabolism. Further investigations into the mechanisms involved and the
role of GSK-3β in this context will provide important insights with relevance to both
skeletal health and metabolic diseases.
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Chapter 5

5

General Discussion and Conclusion
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5.1 Overall Rationale
The focus of this thesis was to investigate the role of GSK-3β in skeletal development.
Although the skeletal roles of proteins upstream or downstream of GSK-3β have been
analyzed extensively, I felt that GSK-3β was a unique kinase and deserved closer
examination. GSK-3β is much more than a regulator of individual pathways, such as the
Wnt pathway or the insulin/IGF pathway.
many anabolic pathways within a cell.

Rather, GSK-3β is a node of regulation for

The web of pathways feeding into and leading

out of GSK-3β appears to vary depending on the cell type and may even vary depending
on context, which explains the high level of discrepancy in the literature. Understanding
GSK-3β’s role in a given tissue is extremely important. This importance is highlighted
by the physiology and biochemical nature of GSK-3β itself. For one thing, there are at
least two completely different ways to inhibit GSK-3β activity, through phosphorylation
or disruption of the destruction complex.

In various studies these two pathways have

been shown to crosstalk, while in others they have been shown to be completely separate
(1-3). To further complicate things there is another protein, GSK-3α, that shares almost
complete sequence homology, but is encoded but a separate gene. Why would evolution
conserve two proteins that were almost identical?

The likely answer is the shear

importance of GSK-3’s role. Indeed it has been shown in many studies that the two
GSK-3 proteins can overlap in function and compensate for each other; however, other
studies have revealed completely separate roles and pathways that they regulate (3-6).
Historically GSK-3α has been largely ignored and the primary focus has been on GSK3β, but I believe (partially based on our data) that greater attention needs to be given to
GSK-3α.
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5.2 Study 1
5.2.1

Experimental Rationale

To explore the role of GSK-3β in skeletal development I employed tissue-specific genetic
manipulation in vivo. The use of pharmacological GSK-3 inhibitors leads to increased
bone mass in both mice and rats (7,8). Genetic manipulation has also shown the role of
GSK-3β in skeletal development in several studies. Ubiquitous deletion of GSK-3β
causes cleft palates, bifid sternum and delayed ossification of sternum, skull, ear bones,
and cranial base (9). Heterozygous deletion of GSK-3β also caused a skeletal phenotype,
namely increased ossification, clavicle abnormalities and increased bone reabsorption
(10). The sum of these studies identify three things; that GSK-3β appears to be important
for skeletal development, that GSK-3α does not compensate completely for the loss of
GSK-3β, and that there are opposing phenotypes with one copy of an allele compared to
the loss of both. The last point is very interesting and suggests that the role of GSK-3β
in bone development is complex. I identified a lack in the literature for GSK-3β and
skeletal development. One under examined area was that no one had identified whether
or not the skeletal effects seen in the whole body GSK-3β heterozygous and homozygous
mutants were cell autonomous to skeletal tissues, or whether they are a secondary effect
to other phenotypes (i.e. result of knocking out GSK-3β in the brain). Another gap was
that no one was able to observe the effect of deleting both alleles of GSK-3β on postnatal
growth and development, since homozygote whole body mutants show perinatal lethality
(9,11). Therefore I sought to explore these issues by using three models: 1. Ex vivo tibia
organ culture treated with pharmacological inhibitors of GSK-3, 2. In vivo cartilagespecific GSK-3β deletion, and 3. In vivo bone-specific GSK-3β deletion.
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5.2.2

Aim 1:

To determine the role of GSK-3β plays in growth plate function, endochondral bone
formation and bone growth.

5.2.3

Hypothesis 1:

Deletion or inhibition of GSK-3β in cartilage causes increased endochondral bone
growth.

5.2.4

Result Summary 1:

I found that treatment of tibia organ cultures with a GSK-3 inhibitor caused the tibia to
grow more over the 6 days in culture. This was expected as I released the anabolic break,
GSK-3. Histological analyses showed that the resting/proliferating zone was longer but
the hypertrophic zone was shorter upon inhibitor treatment, yielding an overall growth
plate length that was not significantly different. Instead, increased length of treated
bones was due to an expanded mineralized zone.

This data together suggested that

increased bone growth was due to increased proliferation, hence the longer
resting/proliferating zone, and increased turn over of hypertrophic chondrocytes, hence
the shorter hypertrophic zone and longer mineralized area.
Another thing that production of cartilage-specific GSK-3β KO should tell us is whether
or not the skeletal defects seen in the whole body KO were due to alterations in the
cartilage (9). The cartilage-specific GSK-3β KO was produced with approximately 80%
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reduction in GSK-3β protein in cartilage. However, the lengths of the KO bones were
not significantly different from the control littermates, and no skeletal phenotypes
resembling those of whole body mutant mice were seen. No histological differences were
seen in the growth plate of cartilage-specific KO mice, suggesting that the effects
observed in our organ cultures were due at least in part to GSK-3α activity. Levels of βcatenin protein in the pre-hypertrophic zone, where GSK-3β is most highly expressed,
was increased in both the ex vivo and in vivo studies. In addition, my data show that
GSK-3α is upregulated to compensate for the loss of GSK-3β protein.

5.2.5

Conclusion 1:

Endochondral bone growth is regulated by one (or both) of the GSK-3 proteins, as seen in
the organ culture experiments, but the in vivo study of the cartilage-specific GSK-3β KO
revealed that GSK-3β was not essential for regulating bone growth. When reviewing the
literature, I see that the GSK-3α global KO is not different in terms of size (12,13), and
the GSK-3β global KO is lethal with skeletal abnormalities (cleft palate and bifurcated
sternum) (9). The heterozygous GSK-3β mice were also shown to have increased bone
mineral density (10). Taken together this data suggests: 1. That likely both Gsk3 genes
have to be deleted or inhibited in chondrocytes to effect growth, 2. That GSK-3β affects
bone development but not through regulation of chondrocyte function.
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5.2.6

Limitations of experimental design 1:

I decided to use tibia organ culture experiments to examine growth over six days in
culture using pharmacological inhibitors of GSK-3. These experiments have several
advantages for studying growth plate chondrocytes: 1. The chondrocytes are assembled in
fully functioning growth plates with all the zones, 2. The tibiae are in a 3D structure as it
would be in vivo, 3. The tibiae grow outward as they would in vivo, 4. The tibiae contain
other cell types that are present in in vivo bones such as osteoblasts, osteoclasts, and
perichondral cells, 5. They are easy to culture and treat, with longitudinal growth as one
measureable outcome. In other words, the tibia organ culture system is as close as
possible to in vivo studies but still maintains the functionality of culturing (e.g. exact
control of culture medium, ease of pharmacological manipulation etc.). However, there
are several important factors that are missing in the organ culture system versus an in
vivo system, such as mechanical stress from the movement and weight of the animal as
well as the influence of the circulatory system. All things considered the tibia organ
culture system is useful to test effects of pharmacological compounds on bone growth.
One thing important thing to clarify is that the GSK-3 inhibitors I used in the organ
culture experiments inhibit both α and β forms. This information is important to interpret
the data correctly especially when comparing the tibia organ culture day with the in vivo
data. Since ex vivo experiments showed that GSK-3 was responsible for regulating
endochondral bone growth, I felt a cartilage-specific GSK-3β deletion in vivo study was
warranted. At first glance the fact that the pharmacological inhibitors inhibits both forms
of GSK-3 appears as a weakness. However, knowing this weakness I can turn it into
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strength by helping us interpret the data by concluding that both GSK-3s must be
inhibited in order to effect bone growth.

5.3 Study 2
5.3.1

Experimental Rationale:

Previous studies showed that GSK-3β controls bone development (9), but no one
determined if this was cell autonomous for skeletal cells, and no one was able to study
postnatal development. Study 1 showed that it the skeletal effects were not a result of
deleting GSK-3β from chondrocytes. For this study I set out to produce osteoblastspecific GSK-3β KO mice to determine its role in skeletal development.

5.3.2

Aim 2:

To determine the role of GSK-3β signaling in osteoblasts during postnatal bone
development.

5.3.3

Hypothesis 2:

Deletion of GSK-3β in osteoblast causes increased bone formation.
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5.3.4

Result Summary 2:

The first observed phenotype of the bone-specific GSK-3β KO mice was that
approximately 30% of the KO mice were dying at birth or shortly after. Some of these
mice were never observed alive; others survived for hours and appeared to be normal and
healthy. Most of the dead pups contained milk in their stomachs and appeared to feed
properly. This was a very interesting phenotype as the global GSK-3β KO mice had
100% mortality at birth (9). This suggests that among all the tissues that GSK-3β was
deleted from in the global KO, bone contributed to the mortality.
The KO mice that survived weighed less than their control littermates. This difference
was about 13% at birth (P0) and increased to 26% by 10 days of age (P10) after which it
remained relatively constant through P21 and beyond. There was no difference between
the heterozygous mice and the controls, which indicates that a homozygous deletion of
GSK-3β is needed to cause the weight phenotype.

This theory is supported in the

literature as the heterozygous global KO did not display any size or weight phenotype
(10). Since I deleted GSK-3β specifically in bone I investigated whether the weight loss
was due to a loss in bone mass. The P0 KO mice had similar lengths of bone to the
control mice; however, by P21 the length of the KO long bones were significantly
shorter. This was an interesting result for two reasons: 1. P0 mice weighed less but their
skeleton was of normal size, and 2. After birth skeletal growth was reduced. Therefore
the weight must be lost from another tissue, which was really interesting in our bonespecific mutants. The other surprising result was that bone growth was reduced while I
would expect increased bone growth from the results of our tibia organ culture
experiments (14). Since growth was affected I examined the growth plate for clues to
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why bone growth was delayed. The main effect on the growth plate was a significantly
larger hypertrophic zone in the KO mice. Proliferation was increased throughout the
proliferating zone, as was the expression of the protein p57 throughout the
prehypertrophic zone. These results would suggest that the bone is growing more as
more chondrocytes are being produced and more are transitioning or differentiating into
hypertrophy. In contrast, apoptosis was reduced in the GSK-3β KO mice which suggests
that the chondrocytes were trapped in hypertrophy, preventing the turnover to bone.
I also observed the same increase in GSK-3α in the prehypertrophic zone of the bonespecific KO mice as I had observed in the cartilage-specific GSK-3β KO mice, likely to
due leaky cre expression in cartilage.

These bone-specific KO mice displayed a

phenotype of delayed skeletal development such as a delay in fusing of bony elements in
the palate, sternum, pelvis, cranium, and vertebrae. On the other hand, there was also
increased bone formed in the P0 mice as shown by longer trabecular bone and higher
amounts of bone in the marrow of mid diaphysis. This was likely to the increase in
proliferation of osteoblasts.

However there was also an increase in the number of

osteoclasts that might be responsible for the normalization of the amount of mineralized
tissue by P21, where only a small difference could be observed.
I also examined the direct effects of GSK-3β deletion on osteoblast signaling (Figure
5.1).

Through the deletion of the negative regulator of both the Wnt and Insulin

pathways, GSK-3β, I examined various cellular markers. I observed an increase in
protein levels of both β-catenin and Runx2, which are both markers of osteoblast
proliferation, differentiation and activity as well as downstream of GSK-3β in the Wnt
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pathway (Figure 5.1).

Likewise I did observe an increase in osteoblast proliferation

determined by PCNA expression and increased osteoblast activity as seen in the
increased trabecular bone. Therefore, GSK-3β regulates osteoblast proliferation and
activity by controlling levels of β-catenin and Runx2 (Figure 5.1).

5.3.5

Conclusion 2:

From these results it can be concluded that osteoblast GSK-3β regulates skeletal
development. Osteoblast GSK-3β is also responsible for the perinatal mortality seen in
our KO mice and contributes to the death seen in the global GSK-3β KO study (9).
Growth was slower postnatally in KO mice, which was opposite to that seen in the organ
culture study (14) and therefore likely caused by secondary effects. P0 KO mice weighed
less but skeletal elements were not any smaller, suggesting that bone GSK-3β is also
regulating tissue that is not bone, likely through an endocrine manner. This conclusion
became much more likely after two papers were published in “Cell” characterizing
osteoblast-specific deletion of the insulin receptor (15,16) which acts upstream of GSK3β.

5.3.6

Limitations of Experimental Design 2:

One major weakness of this study is the nonspecific and leaky expression of the 3.6Kb rat
Col1a1 promoter that was used. The Col I-GSK-3β KO were produced and characterized
to have a 70% reduction of GSK-3β in calvaria/bone samples. However, I also found
that GSK-3β protein in cartilage was also reduced to 55% of the control. This was
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unfortunate as any phenotype discovered could not be attributed with complete certainty
to GSK-3β function in osteoblasts. However, given the results of the cartilage-specific
KO mice which had no skeletal effects (14) I are confident that any skeletal phenotypes
observed are due to the deletion of GSK-3β in osteoblasts.

5.4 Study 3
5.4.1

Experimental Rationale 3:

Our data suggested that weight reduction in our bone-specific mutant mice appeared
earlier and was more severe than reduction in skeletal growth. Additionally, in the
process of aging the mice I discovered that the male KO mice were dying post weaning
between 2-8 months of age.

This did not affect the female mice although their

phenotypes were similar in terms of weight and skeletal effects. This result suggested
that I was indeed dealing with a metabolic phenotype because, how could relative subtle
skeletal phenotypes described in chapter 3 cause death and why just male mortality? Two
studies looking at the osteoblast-specific insulin-receptor KO mice (15,16) discovered
effects on fat content, blood glucose, insulin levels, and insulin sensitivity. The insulin
receptor is just upstream of GSK-3β, which suggested that GSK-3β might also affect
whole body metabolism. Studies involving low birth weight showed that male mice
became more susceptible than females to developing type II diabetes and subsequent
death (17-19), prompting us to particularly focus on glucose metabolism in our mutant
mice.
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5.4.2

Aim 3:

To investigate the whole body metabolic effects of deleting GSK-3β in osteoblasts.

5.4.3

Hypothesis 3:

Deletion of GSK-3β in osteoblasts causes increased insulin signaling, which will in turn
affect whole body metabolism.

5.4.4

Result Summary 3:

To explore the hypothesis that osteoblast GSK-3β was regulating whole body metabolism
I examined the animals blood glucose levels.

The KO animals of both genders had

lower blood glucose in the fed state. The KO mice also displayed lower serum insulin
levels which was surprising at first glance, but made sense in light of their increased
insulin sensitivity since the mutant mice require less insulin to facilitate the uptake of
excess blood glucose. I also showed that circulating leptin and adiponectin were lower in
our KO mice and that the actual size of the adipocytes was smaller. There was concern
that leaky cre expression could be causing these phenotypes, but analyses by IHC,
western blotting, and ELISA assays determined that expression of GSK-3β was normal in
metabolically active tissue.
To further understand the signaling status within the osteoblasts I tested the
phosphorylation status of S6, which is downstream of the insulin receptor but not
downstream of GSK-3β (Figure 5.1). The amount of active S6 was decreased in the
bone-specific GSK-3β KO mice, indicating that like the lower levels of circulating
insulin
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Figure 5.1 (45) Signaling pathways within GSK-3β KO osteoblasts
This schematic represents the signaling pathways affected by deletion of GSK-3β in
osteoblasts. The molecules that were quantified in the study are boxed in red and their
abundance relative to control littermates indicated with either a green arrow for increased
or a red arrow for decreased. The cellular effects are indicated outside the cell.
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resulted in reduced activity of intracellular mediators.

However, insulin-activated

pathways downstream of GSK-3β would be activated despite lower levels of insulin.
This could be one reason why our model does not show the exact opposite phenotype of
the insulin receptor KO models (15,16).
One of the most interesting aspects of bone-specific GSK-3β KO mice is that almost
100% of the male mice die postnatally between 2-8 months of age.

Moreover, male

mice that displayed lower glucose levels early in their life, changed to high glucose levels
prior to premature death. This suggested that these male mice might be more susceptible
than females to developing type II diabetes. These male mice developed damage and
abnormalities throughout the urogenital track prior to death. The most obvious was an
extremely large bladder, 4 times the volume of the control mice, but our analyses showed
that damage throughout the track from the corpus cavernosum to the kidneys preceded
the bladder phenotype.

5.4.5

Conclusion 3:

Osteoblast GSK-3β regulates whole body metabolism by controlling insulin sensitivity.
Male bone-specific GSK-3β KO mice show premature death, possibly because they are
more susceptible to developing type II diabetes.

5.4.6

Limitations of Experimental Design 3:

The weakness of this study is similar to second study, namely the nonspecific or leaky
expression of cre recombinase. As in study 2 the cartilage-specific KO mice did not
display any of the phenotypes described, suggesting that Gsk3b KO in chondrocytes did
not contribute to these phenotypes. I also took great care in examining GSK-3β protein
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levels in key tissues throughout the body to ensure that GSK-3β was not deleted from
other organs of interest. Another weakness is that our studies are not able to pinpoint the
cause of metabolic abnormalities and premature death completely.

5.5 Contribution to Current State of Knowledge Regarding
GSK-3β and Skeletal Development
My first set of experiments focused on the cartilage growth plate. I first examined the
protein expression pattern of both GSK-3α and β throughout the growth plate. This
served several purposes: 1. It was important to establish whether both GSK-3 proteins are
present in the growth plate, 2. The localization of the kinases could suggest the functions
or processes regulated by GSK-3. As mentioned in the introduction, the growth of
endochondral bone is determined by the rate in which chondrocytes cycle through the
stages of the growth plate. Each stage and the transition between each stage are tightly
regulated by various autocrine, paracrine and endocrine signaling pathways. So this
simple experiment of localizing the GSK-3 proteins within the growth plate was also one
of the most important. I showed that GSK-3α was ubiquitously expressed throughout the
growth plate, which suggests a more general role, whereas GSK-3β was primarily found
in the pre-hypertrophic/hypertrophic zone, therefore suggesting that GSK-3β may
regulate the transition to or maintenance of the hypertrophic cells.
Another important aspect that came out of the organ culture experiments was the relation
of GSK-3 to the regulation by PI3K. Through the use of a PI3K inhibitor in double
inhibitor experiments I showed that the regulation of the proliferating zone was PI3Kdependent whereas the hypertrophic zone was PI3K-independent. This is an important

191

contribution to the GSK-3β and cartilage fields as it shows that GSK-3β is regulated by
different pathways within the same cell type, suggesting that regulation can change with
something as subtle as differentiation stage. This requires greater more specific analysis
to determine the mechanism responsible.
One interesting and unexplained result is I still see an increase in β-catenin in the prehypertrophic area of the in vivo model, suggesting that GSK-3β alone regulates β-catenin
in chondrocytes. This fits with the model discussed above where GSK-3 effects on
hypertrophy are PI3K-independent and potentially mediated by the canonical Wnt
pathway. As to the role that this increased β-catenin is playing in the growth plate I were
unable to determine however it appears not to be involved in growth. It has been shown
that inhibition of β-catenin in growth plate cartilage causes postnatal runting (20),
whereas the over expression of β-catenin in cartilage leads to severe skeletal
abnormalities and loss of growth plate organization (21). However, our mice fail to show
much of any cartilage phenotype, so it is unknown what the function of the increased βcatenin the prehypertrophic/hypertrophic zone.
I examined the protein levels of GSK-3α in both cartilage and bone and observed
consistent upregulation of GSK-3α protein when GSK-3β is lost from cartilage; however
there was no change in the bone tissue. This is a very interesting result; it suggests that
this upregulation of GSK-3α is tissue-specific for cartilage, since this effect has not been
reported for any other cell type (to our knowledge). Furthermore, in osteoblasts the
GSK-3α was not upregulated to compensate for the loss of GSK-3β and GSK-3α was
difficult to even detect in the control bone samples. This suggests that in osteoblasts the
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primary GSK-3 is the β form, which lent greater credence that deletion of GSK-3β would
lead to a phenotype.
Our results on the skeletal phenotype of bone-specific Gsk3b-/- mice are interesting for a
couple of reasons: 1. That these bone-specific KO mice have a cartilage phenotype, and
2. That the phenotype of bone growth is the opposite of the organ culture results.

It

would appear that the cartilage phenotype is not a direct result from knocking down
GSK-3β in the cartilage as the cartilage-specific KO (14) did not display a phenotype and
the same suspected compensatory upregulation of GSK-3α was present in both models.
Therefore secondary effects are the likely cause of the cartilage phenotype.

These

secondary effects can occur either through changes in paracrine signaling (e.g. from the
osteoblasts or perichondrium) or from metabolic changes throughout the mouse as seen in
chapter 4. The fact the effect on growth is the opposite of that of GSK-3 inhibitors in the
organ culture model (which contains perichondrium and an ossified core) leads us to
believe that the reason for the reduced growth in the ColI-GSK-3β KO mice is metabolic.
The fact that weight reduction occurs before the delay in bone growth also lends credence
to the metabolic theory.
In our bone-specific KO mice, two different effects appear to act on osteoblasts, the
direct removal of the GSK-3β “brake” in osteoblasts themselves as well as the proposed
systemic metabolic effect.

These two signals result in delayed development and

ossification throughout the skeleton, but an increase in trabecular bone. Interestingly, the
global heterozygous GSK-3β mouse displayed increased trabecular bone (10) whereas
the global homozygous GSK-3β deleted mice displayed skeletal delayed development (9)
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whereas I show that both phenotypes are present in my mutant mice at the same time.

It

appears possible that these seemingly contradictory phenotypes could be due to sitespecific effects of GSK-3β deficiency.
Based on the reduced somatic growth of these mutant mice, and in light of recent findings
that identify bone as regulator of body metabolism, I examined the alterations in
metabolism in our bone-specific Gsk3b KO mice (Figure 5.2). KO mice had lower blood
glucose levels, especially in the fed state. This was specific to osteoblast GSK-3β as the
cartilage-specific GSK-3β KOs did not show any changes in blood glucose levels (Figure
5.2). At this point two studies were published on osteoblast-specific deletion of the
insulin receptor, which effected whole body metabolism, fat content, and insulin
sensitivity (15,16). Since GSK-3β is a negative regulator of the insulin pathway, one
would expect that our bone-specific GSK-3β KO mice would have the opposite
phenotype to the osteoblast-specific insulin receptor KO (Ob-IR KO). Indeed, this is the
case for many parameters such as animal weight and blood glucose levels (Figure 5.2).
Since the Ob-IR KO mice had larger fat content, I examined the adipocyte cell size in
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Figure 5.2 (46) Effects on whole body metabolic signaling
This schematic depicts the documented and proposed signaling changes throughout the
body of the osteoblast-specific GSK-3β KO mice. The parameters boxed in red where
measured in the studies. When a parameter was increased compared to the control it is
indicated by a green arrow, as decrease by a red arrow and no change by a black equal
sign.
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the mutant mice and found they were smaller (Figure 5.2). Likewise, circulating levels of
two hormones synthesized by adipocytes, leptin and adiponectin (Figure 5.2), were
reduced in the bone-specific KO mice.

These data suggest that osteoblast GSK-3β

regulates whole body metabolism by affecting fat deposition and blood glucose levels.
The role of bone as a regulator of body metabolisms is a relatively new and still
controversial concept (15,22,23).

Bones are not static; even in adulthood bones are

undergoing constant remodeling. This process is responsible for maintaining the balance
between the physical demands of the individual to ensure bone integrity, consumption of
energy and minerals and weight of the bones. Given the large mass of bone in the body
this process requires substantial amount of energy. Thus it makes sense that bone is able
to communicate its energy requirements/status to the rest of the body and coordinate
metabolic activities with other tissues.
One parameter in my mice that was not opposite to the Ob-IR KO model was serum
insulin levels, both mutant strains displayed reduced insulin levels (Figure 5.2). The ObIR KO model showed that the reduced insulin was due to a decrease in insulin secretion
(15). These mice also displayed a decrease in insulin tolerance, increase in insulin
resistance (15,16), which means less blood glucose was taken up by the tissues per
specific insulin injection. They also showed as decrease in glucose tolerance (15,16),
which means that it took longer for glucose levels to return to normal after a glucose
injection. Both of these characteristics explain why the Ob-IR KO mice had increased
blood glucose in the fed state, since less insulin is secreted and target tissues are less
responsive to insulin to facilitate glucose uptake. These effects were attributed to the
reduced production of the bone hormone osteocalcin (Ocn), more specifically the
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undercarboxylated form of osteocalcin that directly controls pancreatic islets (15,16).
Our ColI-GSK-3β mice were tested for serum Ocn levels, but showed no differences
(Figure 5.2). Thus it was not surprising when analysis of the pancreas showed no changes
in islet number or size in our mutant mice (Figure 5.2). Nor was there any difference in
glucose tolerance of the ColI-GSK-3β mice, which meant that these mice could clear
excess glucose from the blood stream as efficient as control mice.
With lower insulin levels in our mutant mice, one would expect higher glucose if all other
metabolic parameters are unaffected however, I observed the opposite. There are at least
two possibilities to explain this unexpected result: 1. Insulin is more effective at
facilitating the uptake of glucose in target tissues; therefore less insulin is needed to
uptake excess glucose; or 2. More glucose is used by one or more tissues, resulting in
reduced blood glucose, which in turns results in reduced release of insulin. By injecting
insulin into fasted mice and observing the effects on blood glucose levels over time, I
tested insulin tolerance. Glucose levels were reduced to a larger degree and for an
extended period in mutant mice compared to control mice, which suggests that the mutant
mice are more insulin sensitive (Figure 5.2).

However, disruption of GSK-3β in other

tissues has been shown to increase glucose uptake and insulin stimulated glucose uptake
(24,25).

Although further examination is required, one must wonder, given the size of

the skeleton, whether the direct uptake of glucose by osteoblasts could be causing the
observed metabolic and skeletal phenotypes? For example if mutant osteoblasts have
increased glucose uptake, could this effect be enough to reduce blood glucose and
subsequently affect the growth of the rest of the body?

The reduction in available

glucose could cause the reduction in fat tissue and even growth of the skeleton.
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Therefore probably the most important experiment to conduct on these mice is to figure
out where the glucose is going, which tissue has the increased insulin sensitivity. I know
glucose is not being taken up by the adipocytes, but what about the other classic targets
of insulin such as muscle and the liver? If this is the case, then there must be an unknown
endocrine signal from osteoblasts to induce glucose uptake in these tissues. The other big
question is what about the brain? The brain’s only source of energy is glucose, and brain
function is greatly affected by fluctuation in blood glucose levels. Is the brain being
starved of glucose as it appears in the rest of the body?
In our ColI-GSK-3β KO mice, I was simulating a constant fed state (by activating the
insulin signaling pathway intracellularly) in our osteoblasts, and blood glucose is low
(Figure 5.2). In the Ob-IR KO mice they are simulating a fasted state in their osteoblasts
and blood glucose is high. When interpreting this data, one has to be extremely cautious
as in both cases since I have just altered insulin signaling in bone tissue, whereas the rest
of body will be receiving not only natural ebb and flow of insulin and glucose associated
with eating but whatever effects the altered osteoblasts have on the rest of the body.
There are several aspects of our phenotype that I cannot explain, one being the adipocyte
effects. In our ColI-GSK-3β model the KO mice have increased insulin sensitivity yet
deceased fat mass and more bone (relative to body weight) (Figure 5.2), whereas the ObIR KO mice have the opposite phenotype, more fat, insulin resistance, and less bone.
High adiposity has been shown to increase bone mass and vice versa (26), but the
opposite is occurring in both our mice and the Ob-IR KO mice.
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The final and maybe most interesting aspect of the ColI-GSK-3β KO mice is the sudden
death of the male mice. I am unsure if this death is related to death seen in 30% of the
KO mice just after birth. Although not tested, I do not believe that these P0 deaths were
all male since the ratio of genders for surviving mice was approximately 50:50. This
finding is extremely interesting, as I may have found a model for the study of malespecific development of diabetes. Understanding why the females are unaffected is also
important and lead to therapeutic treatments of high-risk males.

5.6 Overall Conclusion
I have made some significant contributions to understanding the complex role of GSK-3β
in the skeleton and beyond. This greater understanding of GSK-3β function in both
cartilage and bone may lead to new insight for researchers studying other tissues. I also
successfully showed that these were worthwhile experiments to conduct. Others studies
have examined molecules both upstream and downstream of GSK-3β, but none of these
models expect the insulin receptor studies (15,16) have shown metabolic changes.
Furthermore, although GSK-3β is downstream of the insulin receptor, the phenotype was
not the exact opposite, very likely due to GSK-3β’s role in many other signaling
pathways. Thus, our studies also contributed to a greater understanding of the complex
nature of the regulation of whole body metabolism by bone.
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